<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Med Chem</journal-id><journal-title-group><journal-title>European Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0223-5234</issn><issn pub-type="epub">1768-3254</issn><publisher><publisher-name>Elsevier Masson SAS.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7457942</article-id><article-id pub-id-type="publisher-id">S0223-5234(20)30762-5</article-id><article-id pub-id-type="doi">10.1016/j.ejmech.2020.112790</article-id><article-id pub-id-type="publisher-id">112790</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Antiviral potential of natural products from marine microbes</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Yi</surname><given-names>Mengqi</given-names></name></contrib><contrib contrib-type="author" id="au2"><name><surname>Lin</surname><given-names>Sixiao</given-names></name></contrib><contrib contrib-type="author" id="au3"><name><surname>Zhang</surname><given-names>Bin</given-names></name></contrib><contrib contrib-type="author" id="au4"><name><surname>Jin</surname><given-names>Haixiao</given-names></name></contrib><contrib contrib-type="author" id="au5"><name><surname>Ding</surname><given-names>Lijian</given-names></name><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1">Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, 315832, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author.</corresp></author-notes><pub-date pub-type="pmc-release"><day>31</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>1</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2020</year></pub-date><volume>207</volume><fpage>112790</fpage><lpage>112790</lpage><history><date date-type="received"><day>18</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>25</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Masson SAS. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Masson SAS</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Humans have been suffered from viral infections over the centuries, such as influenza, HSV, and HIV, which have killed millions of people worldwide. However, the availability of effective treatments for infectious diseases remains limited until now, as most of the viral pathogens resisted to many medical treatments. Marine microbes are currently one of the most copious sources of pharmacologically active natural products, which have constantly provided promising antivirus agents. To date, a large number of marine microbial secondary metabolites with antiviral activities have been widely reported. In this review, we have summarized the potential antivirus compounds from marine microorganisms over the last decade. In addition, the structures, bioactivities, and origins of these compounds were discussed as well.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic xlink:href="fx1_lrg"/></fig></p></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Marine microbes-derived natural products with various antiviral activities were summarized (2009&#x02013;2019).</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">18 compounds demonstrated significant antivirus activities stronger than the corresponding positive drugs.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">This review highlighted the potential development of these natural products as antiviral lead compounds.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Marine microbes</kwd><kwd>Marine natural products</kwd><kwd>Antivirus</kwd><kwd>Anti-influenza</kwd><kwd>Anti-HSV</kwd><kwd>Anti-HIV</kwd></kwd-group><kwd-group id="kwrds0015"><title>Abbreviations</title><kwd>HSV, Herpes simplex</kwd><kwd>HIV, Human immunodeficiency virus</kwd><kwd>HCV, Hepatitis C virus</kwd><kwd>RSV, Respiratory syncytial virus</kwd><kwd>EV71, Enterovirus 71</kwd><kwd>DENV, Dengue virus</kwd><kwd>COVID-19, Coronavirus disease 2019</kwd><kwd>SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2</kwd><kwd>CHIKV, Chikungunya virus</kwd><kwd>WEEV, Western equine encephalitis virus</kwd><kwd>CPE, Cythopathic effect</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0025">As we all know, viral infections are the main reasons for human death worldwide [<xref rid="bib1" ref-type="bibr">1</xref>]. Several infectious viral diseases occurred so far have been reported, which involve viruses such as influenza [<xref rid="bib2" ref-type="bibr">2</xref>], Herpes Simplex Virus (HSV) [<xref rid="bib3" ref-type="bibr">3</xref>], Human Immunodeficiency Virus (HIV) [<xref rid="bib4" ref-type="bibr">4</xref>], Respiratory Syncytial Virus (RSV) [<xref rid="bib5" ref-type="bibr">5</xref>], Enterovirus 71 (EV71) [<xref rid="bib6" ref-type="bibr">6</xref>], Dengue Virus (DENV) [<xref rid="bib7" ref-type="bibr">7</xref>], Ebola Virus [<xref rid="bib8" ref-type="bibr">8</xref>], as well as the recently emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<xref rid="bib9" ref-type="bibr">9</xref>]. The main characteristic of viruses is that their genomes are easily mutated, making it difficult to control viral infections and causing pandemics worldwide. Meanwhile, in the absence of vaccines and antiviral therapies, the rapid spread of the virus has been accelerated by increased migration, global travel and urbanization [<xref rid="bib10" ref-type="bibr">10</xref>]. However, most antiviral drugs today have adverse drug reactions and develop viral resistance to treatments. The threat of drug resistance not only results in huge challenges to the clinical management of viral infections, but also places a heavy burden on the global economy [<xref rid="bib11" ref-type="bibr">11</xref>]. Although considerable progress has been made in the development of antiviral drugs since acyclovir, a nucleoside analogue, was invented in 1960, novel drugs that can work through different mechanisms to combat resistance are still desperately in need [<xref rid="bib12" ref-type="bibr">12</xref>]. In recent years, with the development of virology, many virus-specific processes or proteins have been identified as targets for chemotherapy [<xref rid="bib13" ref-type="bibr">13</xref>]. Viral replication cycle includes viral adsorption, viral cell fusion, reverse transcription, integration, translation and other steps, which can be used as targets for antiviral drugs [<xref rid="bib14" ref-type="bibr">14</xref>]. In addition, specific viral enzymes which involve the synthesis of viral DNA, RNA and glycoproteins are also potential targets [<xref rid="bib15" ref-type="bibr">15</xref>]. For example, acyclovir disturbs some key herpes virus enzymes that have an affinity for nucleotide analogues [<xref rid="bib16" ref-type="bibr">16</xref>]. Despite the successful understanding of viral proliferation cycle and comprehensive studies for suitable vaccines and treatments against viral infections over the past half of century, still several infections such as HIV afflict a substantial proportion of the world populations in all generations [<xref rid="bib17" ref-type="bibr">17</xref>]. There is no definite vaccine against numerous prevalent viral infections, including most respiratory-tract viruses, HSV-1 and HSV-2 or DEVN [<xref rid="bib18" ref-type="bibr">18</xref>]. Moreover, drug resistance to available antiviral agents by different viruses such as the HIV type 1 or HSV-1 has always been a serious impediment to treatment of viral infections, stimulating the search for new efficient molecules [<xref rid="bib16" ref-type="bibr">16</xref>,<xref rid="bib17" ref-type="bibr">17</xref>].</p><p id="p0030">Recently, the ocean has arisen great attention from scholars and practitioners, as many marine derived secondary metabolites with evidently anti-inflammatory, antitumor, antimicrobial, antiviral, antimalarial, and antioxidant activities have been discovered [<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib20" ref-type="bibr">20</xref>]. According to the MarinLit database, annually more than 1200 novel natural products were reported from a variety of marine sources, such as algae, corals, sponges, and especially microorganisms [<xref rid="bib19" ref-type="bibr">19</xref>]. Moreover, these antivirus natural compounds even have entered the advanced stages of clinical trials, several of which are commercially available. For example, vidarabine is currently used for the treatment of HSV infection, whose lead structure, spongouridine, was originally isolated from the marine sponge [<xref rid="bib21" ref-type="bibr">21</xref>]. Marine microbes have become a promising reservoir of new antivirus secondary metabolites [<xref rid="bib22" ref-type="bibr">22</xref>]. There are about 1 million microorganisms in 1&#x000a0;mL of seawater, including some cyanobacteria, actinomyces, bacteria, and fungi, which have great potential in the pharmaceutical research [<xref rid="bib23" ref-type="bibr">23</xref>]. In addition, some of marine microorganisms rely on the symbiosis with marine animals and plants to acquire nutrition, but due to fierce competition, they have metabolized some specific molecules to obtain extremely limited resources [<xref rid="bib24" ref-type="bibr">24</xref>]. These secondary metabolites can chemically be divided into alkaloids, peptides, polyketides, terpenoids, etc, which contained diverse biological functions such as antibacterial, antiviral and antitumor activities. Excitingly, cyanobacterial-derived cyanovirin N has been utilized as anti-HIV compound in preclinical development [<xref rid="bib25" ref-type="bibr">25</xref>]. However, only limited natural compounds discovered from marine microbes have been used in clinical research, reflecting the lack of understanding and development of marine microbial resources [<xref rid="bib26" ref-type="bibr">26</xref>].</p><p id="p0035">This review provided a comprehensive overview of 79 natural products derived from marine microbes over the last decade, presenting various antiviral activities, including anti-influenza (48%) anti-HSV (33%), and others (19%) (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>
). These secondary metabolites were mainly isolated from marine microbes <italic>Aspergillus</italic>, <italic>Penicillium</italic> and <italic>Streptomyces</italic> discovered from the marine environment of different countries (<xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref>, <xref rid="fig3" ref-type="fig">Fig.&#x000a0;3</xref>
). Most of antiviral molecules (<xref rid="fig3" ref-type="fig">Fig.&#x000a0;3</xref>) were obtained from marine microbes sampled in China. 18 secondary metabolites, such as truncateol O (<bold>16</bold>) and <italic>R</italic>-wailupemycin K (<bold>18</bold>), displayed significant antiviral activities even more effective than those of the positive drugs [<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>]. <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref> and <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>
listed the name, isolation source (marine microbes) and the antiviral activities of these compounds.<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>The percentage of antiviral compounds isolated from marine microbes according to anti-virus types.</p></caption><alt-text id="alttext0015">Fig.&#x000a0;1</alt-text><graphic xlink:href="gr1_lrg"/></fig><fig id="fig2"><label>Fig.&#x000a0;2</label><caption><p>The number of antiviral compounds isolated from marine microbes according to genera and sampling sources.</p></caption><alt-text id="alttext0020">Fig.&#x000a0;2</alt-text><graphic xlink:href="gr2_lrg"/></fig><fig id="fig3"><label>Fig.&#x000a0;3</label><caption><p>Marine microbial sampling sites for new and known antiviral compounds reported from 2009 to 2019.</p></caption><alt-text id="alttext0025">Fig.&#x000a0;3</alt-text><graphic xlink:href="gr3_lrg"/></fig><table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Secondary metabolites with anti-H<sub>1</sub>N<sub>1</sub> and anti-H<sub>3</sub>N<sub>2</sub> activities from marine microbes.</p></caption><alt-text id="alttext0105">Table&#x000a0;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Metabolites</th><th>Species</th><th>Activities</th><th>Ref</th></tr></thead><tbody><tr><td align="left">Rubrolide S (<bold>1</bold>)</td><td align="left"><italic>A.&#x000a0;terreus</italic> OUCMDZ-1925.</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;87.1&#x000a0;&#x003bc;M&#x000a0;(H<sub>1</sub>N<sub>1</sub> virus).</td><td align="left">[<xref rid="bib33" ref-type="bibr">33</xref>]</td></tr><tr><td align="left">VLPs Q&#x02013;T (<bold>2</bold>&#x02013;<bold>5</bold>)</td><td align="left"><italic>S.&#x000a0;youssoufiensis</italic> OUC6819</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;30.6&#x02013;68.4&#x000a0;&#x003bc;M, resp. (H<sub>1</sub>N<sub>1</sub> virus) IC<sub>50</sub>&#x000a0;= 45.3&#x02013;95.0 &#x003bc;M, resp. (H<sub>3</sub>N<sub>2</sub> virus)</td><td align="left">[<xref rid="bib34" ref-type="bibr">34</xref>]</td></tr><tr><td align="left">Cladosin C (<bold>6</bold>)</td><td align="left"><italic>C.&#x000a0;sphaerospermum</italic> 2005-01-E3</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;276&#x000a0;&#x003bc;M&#x000a0;(H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left">Sorbicatechol A (<bold>7</bold>), B (<bold>8</bold>)</td><td align="left"><italic>P.&#x000a0;chrysogenum</italic> PJX-17</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;85 and 113&#x000a0;&#x003bc;M, resp. (H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib36" ref-type="bibr">36</xref>]</td></tr><tr><td align="left">(3<italic>Z</italic>,6<italic>Z</italic>)-3-(4-hydroxybenzylidene)-6-isobutylidenepiperazine-2,5-dione (<bold>9</bold>) (3Z,6S)-3-benzylidene-6-isobutylpiperazine-2,5-dione (<bold>10</bold>) Albonoursin (<bold>11</bold>)</td><td align="left"><italic>Streptomyces</italic> sp. FXJ7.328</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;41.5&#x000a0;&#x000b1;&#x000a0;4.5, 28.9&#x000a0;&#x000b1;&#x000a0;2.2 and 6.8&#x000a0;&#x000b1;&#x000a0;1.5&#x000a0;&#x003bc;M, resp. (H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib37" ref-type="bibr">37</xref>]</td></tr><tr><td align="left">Isoaspulvinone E (<bold>12</bold>)<break/>Aspulvinone E (<bold>13</bold>)<break/>Pulvic acid (<bold>14</bold>)</td><td align="left"><italic>A.&#x000a0;terreus</italic> Gwq-48</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;32.3, 56.9, and 29.1&#x000a0;&#x003bc;g/mL, resp. (H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib38" ref-type="bibr">38</xref>]</td></tr><tr><td align="left">Anthranoside C (<bold>15</bold>)</td><td align="left"><italic>Streptomyces</italic> sp. CMN-62</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;171&#x000a0;&#x003bc;M&#x000a0;(H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib39" ref-type="bibr">39</xref>]</td></tr><tr><td align="left">Truncateol O (<bold>16</bold>)</td><td align="left"><italic>T.&#x000a0;angustata</italic> XSB-01-43</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;30.4&#x000a0;&#x003bc;M&#x000a0;(H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib27" ref-type="bibr">27</xref>]</td></tr><tr><td align="left">Wailupemycin J (<bold>17</bold>) <italic>R</italic>-wailupemycin K (<bold>18</bold>)<break/>Deoxyenterocin (<bold>19</bold>)</td><td align="left"><italic>Streptomyces</italic> sp. OUCMDZ-3434</td><td align="left">47.8%, 42.5% and 60.6% inhibitions at 50&#x000a0;&#x003bc;g/mL, resp. (H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib28" ref-type="bibr">28</xref>]</td></tr><tr><td align="left">Chrodrimanin K (<bold>20</bold>), N (<bold>21</bold>) 3-Hydroxypentacecilide A (<bold>22</bold>)</td><td align="left"><italic>Penicillium</italic> sp. SCS-KFD09</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;74, 58, and 34&#x000a0;&#x003bc;M, resp. (H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib40" ref-type="bibr">40</xref>]</td></tr><tr><td align="left">Asteltoxins E (<bold>23</bold>), F (<bold>24</bold>)</td><td align="left"><italic>Aspergillus</italic> sp. SCSIO XWS02F40</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;3.5&#x000a0;&#x000b1;&#x000a0;1.3&#x000a0;&#x003bc;M&#x000a0;(H<sub>1</sub>N<sub>1</sub> virus)<break/>IC<sub>50</sub>&#x000a0;=&#x000a0;6.2&#x000a0;&#x000b1;&#x000a0;0.08 and 8.9&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;&#x003bc;M, resp. (H<sub>3</sub>N<sub>2</sub> virus)</td><td align="left">[<xref rid="bib41" ref-type="bibr">41</xref>]</td></tr><tr><td align="left">6-<italic>O</italic>-demethylmonocerin (<bold>25</bold>)<break/>(+)-Monocerin (<bold>26</bold>)</td><td align="left"><italic>Aspergillus</italic> sp. OUCMDZ-1583</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;172.4 and 175.5&#x000a0;&#x003bc;M, resp. (H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib42" ref-type="bibr">42</xref>]</td></tr><tr><td align="left">Indole diterpenoids (<bold>27</bold>&#x02013;<bold>31</bold>)<break/>Emindole SB (<bold>32</bold>)<break/>21-Isopentenylpaxilline (<bold>33</bold>)<break/>Paspaline (<bold>34</bold>)<break/>Paxilline (<bold>35</bold>)</td><td align="left"><italic>P.&#x000a0;camemberti</italic> OUCMDZ-1492</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;28.3, 38.9, 32.2, 73.3, 34.1, 26.2, 6.6, 77.9, and 17.7&#x000a0;&#x003bc;M, resp. (H<sub>1</sub>N<sub>1</sub> virus)</td><td align="left">[<xref rid="bib43" ref-type="bibr">43</xref>]</td></tr><tr><td align="left">Asperterrestide A (<bold>36</bold>)</td><td align="left"><italic>A.&#x000a0;terreus</italic> SCSGAF0162</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;20.2 and 0.41&#x000a0;&#x003bc;M, resp. (H<sub>1</sub>N<sub>1</sub> and H<sub>3</sub>N<sub>2</sub> virus)</td><td align="left">[<xref rid="bib44" ref-type="bibr">44</xref>]</td></tr><tr><td align="left">Cladosporisteroid B (<bold>37</bold>)</td><td align="left"><italic>Cladosporium</italic> sp. SCSIO41007</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;16.2&#x000a0;&#x003bc;M&#x000a0;(H<sub>3</sub>N<sub>2</sub> virus)</td><td align="left">[<xref rid="bib45" ref-type="bibr">45</xref>]</td></tr><tr><td align="left">6<italic>&#x003b2;</italic>,9<italic>&#x003b1;</italic>-dihydroxy-14-<italic>p</italic>-nitrobenzoylcinnamolide (<bold>38</bold>)</td><td align="left"><italic>A.&#x000a0;ochraceus</italic> Jcma1F17</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;17.0&#x000a0;&#x003bc;M&#x000a0;(H<sub>3</sub>N<sub>2</sub> virus)</td><td align="left">[<xref rid="bib46" ref-type="bibr">46</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Secondary metabolites with anti-HSV activities from marine microbes.</p></caption><alt-text id="alttext0110">Table&#x000a0;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Metabolites</th><th>Species</th><th>Activities</th><th>Ref.</th></tr></thead><tbody><tr><td align="left">(4<italic>S</italic>)-10-hydroxy-10-methyl-11-oxo-dodec-2-en-1,4-olide (<bold>39</bold>)</td><td align="left"><italic>S.&#x000a0;koyangensis</italic></td><td align="left">EC<sub>50</sub>&#x000a0;=&#x000a0;25.4&#x000a0;&#x003bc;M (HSV-1 virus)</td><td align="left">[<xref rid="bib53" ref-type="bibr">53</xref>]</td></tr><tr><td align="left">Simplicilliumtide J (<bold>40</bold>)<break/>Verlamelin A (<bold>41</bold>), B (<bold>42</bold>)</td><td align="left"><italic>S.&#x000a0;obclavatum</italic></td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;14.0, 16.7, and 15.6&#x000a0;&#x003bc;M, resp. (HSV-1 virus)</td><td align="left">[<xref rid="bib54" ref-type="bibr">54</xref>]</td></tr><tr><td align="left">Aspergilols H (<bold>43</bold>), I (<bold>44</bold>)<break/>Coccoquinone A (<bold>45</bold>)</td><td align="left"><italic>A.&#x000a0;versicolor</italic> SCSIO 41502</td><td align="left">EC<sub>50</sub>&#x000a0;=&#x000a0;4.68, 6.25, and 3.12&#x000a0;&#x003bc;M, resp. (HSV-1 virus)</td><td align="left">[<xref rid="bib55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left">Trichobotrysins A (<bold>46</bold>), B (<bold>47</bold>), D (<bold>48</bold>)</td><td align="left"><italic>T.&#x000a0;effusa</italic> DFFSCS021</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;3.08, 9.37, and 3.12&#x000a0;&#x003bc;M, resp. (HSV-1 virus)</td><td align="left">[<xref rid="bib56" ref-type="bibr">56</xref>]</td></tr><tr><td align="left">Acremonpeptides A (<bold>49</bold>), B (<bold>50</bold>) Al(III)-acremonpeptide D (<bold>51</bold>)</td><td align="left"><italic>A.&#x000a0;persicinum</italic> SCSIO 115</td><td align="left">EC<sub>50</sub>&#x000a0;=&#x000a0;16, 8.7, and 14&#x000a0;&#x003bc;M, resp. (HSV-1 virus)</td><td align="left">[<xref rid="bib57" ref-type="bibr">57</xref>]</td></tr><tr><td align="left">Aspergillipeptides D (<bold>52</bold>), E (<bold>53</bold>)</td><td align="left"><italic>Aspergillus</italic> sp. SCSIO 41501</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;9.5 and 19.8&#x000a0;&#x003bc;M, resp. (HSV-1 virus)</td><td align="left">[<xref rid="bib58" ref-type="bibr">58</xref>]</td></tr><tr><td align="left">12&#x003b1;-Dehydroxyisoterreulactone A (<bold>54</bold>)<break/>Arisugacin A (<bold>55</bold>)<break/>Isobutyrolactone II (<bold>56</bold>)<break/>Aspernolide A (<bold>57</bold>)</td><td align="left"><italic>A.&#x000a0;terreus</italic> SCSGAF0162</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;16.4&#x000a0;&#x000b1;&#x000a0;0.6, 6.34&#x000a0;&#x000b1;&#x000a0;0.4, 21.8&#x000a0;&#x000b1;&#x000a0;0.8 and 28.9&#x000a0;&#x000b1;&#x000a0;0.8&#x000a0;&#x003bc;g/mL, resp. (HSV-1 virus)</td><td align="left">[<xref rid="bib59" ref-type="bibr">59</xref>]</td></tr><tr><td align="left">Balticolid (<bold>58</bold>)</td><td align="left">Marine ascomycetous strain 222</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;0.45&#x000a0;&#x003bc;M (HSV-1 virus)</td><td align="left">[<xref rid="bib60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left">Balticols A&#x02212;F (<bold>59&#x02013;64</bold>)</td><td align="left">Marine ascomycetous strain 222</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;1, 1, 1, 0.1, 0.01, 0.1&#x000a0;&#x003bc;g/mL, resp. (HSV-1 virus)</td><td align="left">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Secondary metabolites with other antivirus activities from marine microbes.</p></caption><alt-text id="alttext0115">Table&#x000a0;3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Metabolites</th><th>Species</th><th>Activities</th><th>Ref</th></tr></thead><tbody><tr><td align="left">Truncateols O (<bold>2</bold>), P (<bold>65</bold>)</td><td align="left"><italic>T.&#x000a0;angustata</italic></td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;39.0 and 16.1&#x000a0;&#x003bc;M, resp. (HIV virus)</td><td align="left">[<xref rid="bib27" ref-type="bibr">27</xref>]</td></tr><tr><td align="left">Trypilepyrazinol (<bold>66</bold>)<break/>3<italic>&#x003b2;</italic>-hydroxyergosta-8,14,24 (28)-trien-7-one (<bold>67</bold>)</td><td align="left"><italic>Penicillium</italic> sp. IMB17-046</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;4.6 and 3.5&#x000a0;&#x003bc;M, resp. (HIV-1 virus)<break/>IC<sub>50</sub>&#x000a0;=&#x000a0;7.7&#x000a0;&#x003bc;M (HCV virus)</td><td align="left">[<xref rid="bib66" ref-type="bibr">66</xref>]</td></tr><tr><td align="left">Aspernigrin C (<bold>68</bold>)<break/>Malformin C (<bold>69</bold>)</td><td align="left"><italic>A.&#x000a0;niger</italic> SCSIO Jcsw6F30</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;4.7&#x000a0;&#x000b1;&#x000a0;0.4 and 1.4&#x000a0;&#x000b1;&#x000a0;0.06&#x000a0;&#x003bc;M, resp. (HIV-1 virus)</td><td align="left">[<xref rid="bib67" ref-type="bibr">67</xref>]</td></tr><tr><td align="left">3&#x003b1;-hydroxy-7-ene-6,20-dione (<bold>70</bold>)</td><td align="left"><italic>Cladosporium</italic> sp. WZ-2008-0042</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;0.12&#x000a0;mM (RSV virus)</td><td align="left">[<xref rid="bib70" ref-type="bibr">70</xref>]</td></tr><tr><td align="left">Cytosporin L (<bold>71</bold>)<break/>Cytosporin D (<bold>72</bold>)</td><td align="left"><italic>Eutypella</italic> sp.</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;72.01 and 30.25&#x000a0;&#x003bc;M, resp. (RSV virus)</td><td align="left">[<xref rid="bib71" ref-type="bibr">71</xref>]</td></tr><tr><td align="left">Penicitrinone F (<bold>73</bold>)</td><td align="left"><italic>P.&#x000a0;chrysogenum</italic> SCSIO 41001</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;14.5&#x000a0;&#x003bc;M (EV71 virus)</td><td align="left">[<xref rid="bib74" ref-type="bibr">74</xref>]</td></tr><tr><td align="left">6<italic>&#x003b2;</italic>,9<italic>&#x003b1;</italic>-dihydroxy-14-<italic>p</italic>-nitrobenzoylcinnamolide (<bold>38</bold>)</td><td align="left"><italic>A.&#x000a0;ochraceus</italic> Jcma1F17</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;9.4&#x000a0;&#x003bc;M (EV71 virus)</td><td align="left">[<xref rid="bib46" ref-type="bibr">46</xref>]</td></tr><tr><td align="left">ZSU-H85 A (<bold>74</bold>)</td><td align="left"><italic>Trichoderma</italic> sp. SCSIO41004</td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;25.7&#x000a0;&#x003bc;M (EV71 virus)</td><td align="left">[<xref rid="bib75" ref-type="bibr">75</xref>]</td></tr><tr><td align="left">Scequinadoline A (<bold>75</bold>)</td><td align="left"><italic>D.&#x000a0;cejpii</italic> F31-1</td><td align="left">50% inhibition, at 50&#x000a0;&#x003bc;M (DENV virus)</td><td align="left">[<xref rid="bib77" ref-type="bibr">77</xref>]</td></tr><tr><td align="left">Debromoaplysiatoxin (<bold>76</bold>) Anhydrodebromoaplysiatoxin (<bold>77</bold>)<break/>3-Methoxydebromoaplysiatoxin (7<bold>8</bold>)</td><td align="left"><italic>T.&#x000a0;erythraeum</italic></td><td align="left">EC<sub>50</sub>&#x000a0;=&#x000a0;1.3, 22.3 and 2.7&#x000a0;&#x003bc;M, resp. (CHIKV virus)</td><td align="left">[<xref rid="bib79" ref-type="bibr">79</xref>]</td></tr><tr><td align="left">Antimycin A10a (<bold>79</bold>)</td><td align="left"><italic>S.&#x000a0;kaviengensis</italic></td><td align="left">IC<sub>50</sub>&#x000a0;=&#x000a0;3&#x000a0;nM (WEEV virus)</td><td align="left">[<xref rid="bib81" ref-type="bibr">81</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="sec2"><label>2</label><title>Potential anti-virus agents from marine microbes</title><sec id="sec2.1"><label>2.1</label><title>Anti-influenza virus compounds</title><p id="p0040">Among human influenza viruses, influenza A virus is the most susceptible to mutations causing worldwide pandemics many times, such as 1918 Spanish flu pandemic [<xref rid="bib29" ref-type="bibr">29</xref>]. Influenza viruses contain two functional surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA) [<xref rid="bib30" ref-type="bibr">30</xref>]. NA has become a major target for drug design against influenza virus as it acts as a significant role in influenza virus replication and has highly protected active site [<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib32" ref-type="bibr">32</xref>]. Rubrolide S (<bold>1</bold>, <xref rid="fig4" ref-type="fig">Fig.&#x000a0;4</xref>
), a new rubrolide, was first discovered in the fermentation broth of the marine-derived fungus <italic>Aspergillus terreus</italic> OUCMDZ-1925 that was isolated in viscera of the barracuda (<italic>Chelon haematocheilus</italic>) grown in the Yellow River [<xref rid="bib33" ref-type="bibr">33</xref>]. This compound displayed significant inhibitory activity toward H<sub>1</sub>N<sub>1</sub> virus with IC<sub>50</sub> value of 87.1&#x000a0;&#x003bc;M (ribavirin as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;118.8&#x000a0;&#x003bc;M) [<xref rid="bib33" ref-type="bibr">33</xref>]. Chemical study of marine-derived <italic>Streptomyces youssoufiensis</italic> OUC6819 discovered that heterologous expression of the type III polyketide synthase (PKS) gene vioA resulted in production of four novel violapyrones (VLPs), VLPs Q&#x02013;T (<bold>2</bold>&#x02013;<bold>5</bold>, <xref rid="fig4" ref-type="fig">Fig.&#x000a0;4</xref>) [<xref rid="bib34" ref-type="bibr">34</xref>]. Using ribavirin as a positive control, anti-influenza A [H<sub>1</sub>N<sub>1</sub> (A/Virginia/ATCC1/2009) and H<sub>3</sub>N<sub>2</sub> (A/Aichi/2/1968)] virus activity of VLPs were evaluated [<xref rid="bib34" ref-type="bibr">34</xref>]. The results showed that these VLPs exhibited considerable anti-H<sub>1</sub>N<sub>1</sub> and anti-H<sub>3</sub>N<sub>2</sub> activities with IC<sub>50</sub> values of 30.6&#x02013;68.4&#x000a0;&#x003bc;M and 45.3&#x02013;95.0&#x000a0;&#x003bc;M, respectively (ribavirin as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;66.7 and 99.6&#x000a0;&#x003bc;M, respectively) [<xref rid="bib34" ref-type="bibr">34</xref>]. The strain <italic>Cladosporium sphaerospermum</italic> 2005-01-E3, isolated from sediments collected in the Pacific Ocean, resulted in the isolation of a new hybrid polyketide, cladosin C (<bold>6</bold>, <xref rid="fig4" ref-type="fig">Fig.&#x000a0;4</xref>) [<xref rid="bib35" ref-type="bibr">35</xref>]. Compound <bold>6</bold> exhibited anti-influenza A H<sub>1</sub>N<sub>1</sub> virus activity with IC<sub>50</sub> value of 276&#x000a0;&#x003bc;M (ribavirin as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;131&#x000a0;&#x003bc;M) [<xref rid="bib35" ref-type="bibr">35</xref>]. Another marine fungus <italic>Penicillium chrysogenum</italic> PJX-17 was derived from a soft coral collected at Terra Nova bay, Antarctica. Chemical investigation of the fungus <italic>P.&#x000a0;chrysogenum</italic> PJX-17 afforded two novel sorbicillinoids combining a bicycle [2.2.2] octane with a 2-methoxyphenol moiety, named sorbicatechols A (<bold>7</bold>, <xref rid="fig4" ref-type="fig">Fig.&#x000a0;4)</xref> and B (<bold>8</bold>, <xref rid="fig4" ref-type="fig">Fig.&#x000a0;4</xref>) [<xref rid="bib36" ref-type="bibr">36</xref>]. These compounds showed inhibitory activities against H<sub>1</sub>N<sub>1</sub> virus, with IC<sub>50</sub> values of 85 and 113&#x000a0;&#x003bc;M, respectively (ribavirin as a positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;84&#x000a0;&#x003bc;M) [<xref rid="bib36" ref-type="bibr">36</xref>].<fig id="fig4"><label>Fig.&#x000a0;4</label><caption><p>Chemical structures of compounds <bold>1</bold>&#x02013;<bold>8</bold> with anti-H<sub>1</sub>N<sub>1</sub> activities.</p></caption><alt-text id="alttext0030">Fig.&#x000a0;4</alt-text><graphic xlink:href="gr4_lrg"/></fig></p><p id="p0045">A new diketopiperazine derivative (3<italic>Z</italic>,6<italic>Z</italic>)-3-(4-hydroxybenzylidene)-6-isobutylidenepiperazine-2,5-dione (<bold>9</bold>, <xref rid="fig5" ref-type="fig">Fig.&#x000a0;5</xref>
), two known analogues, (3<italic>Z</italic>,6<italic>S</italic>)-3-benzylidene-6-isobutylpiperazine-2,5-dione (<bold>10</bold>, <xref rid="fig5" ref-type="fig">Fig.&#x000a0;5</xref>) and albonoursin (<bold>11</bold>, <xref rid="fig5" ref-type="fig">Fig.&#x000a0;5</xref>) were separated from the extract of marine-derived <italic>Streptomyces</italic> sp. FXJ7.328 collected from coastal sediment at Huanghai beach [<xref rid="bib37" ref-type="bibr">37</xref>]. Compound <bold>9</bold> showed anti-H<sub>1</sub>N<sub>1</sub> virus with IC<sub>50</sub> value of 41.5&#x000a0;&#x000b1;&#x000a0;4.5&#x000a0;&#x003bc;M. In addition, compound <bold>10</bold> and <bold>11</bold> showed potent activity against influenza A (H<sub>1</sub>N<sub>1</sub>) virus with IC<sub>50</sub> values of 28.9&#x000a0;&#x000b1;&#x000a0;2.2 and 6.8&#x000a0;&#x000b1;&#x000a0;1.5&#x000a0;&#x003bc;M, respectively (ribavirin as a positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;38.8&#x000a0;&#x000b1;&#x000a0;1.5&#x000a0;&#x003bc;M [<xref rid="bib37" ref-type="bibr">37</xref>]. The strain identified as <italic>Aspergillus terreus</italic> Gwq-48, which was isolated from a mangrove rhizosphere soil sample collected in the coast of Fujian province resulted in the discovery of a new butenolide isoaspulvinone E (<bold>12</bold>, <xref rid="fig5" ref-type="fig">Fig.&#x000a0;5</xref>), together with two known butenolides aspulvinone E (<bold>13</bold>, <xref rid="fig5" ref-type="fig">Fig.&#x000a0;5</xref>) and pulvic acid (<bold>14</bold>, <xref rid="fig5" ref-type="fig">Fig.&#x000a0;5</xref>) [<xref rid="bib38" ref-type="bibr">38</xref>]. These compounds displayed significant inhibitory activities against H<sub>1</sub>N<sub>1</sub> virus, with IC<sub>50</sub> values of 32.3, 56.9, and 29.1&#x000a0;&#x003bc;g/mL, respectively (ribavirin as a positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;24.6&#x000a0;&#x003bc;g/mL; Zanamivir as a positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;28.4&#x000a0;&#x003bc;g/mL) [<xref rid="bib38" ref-type="bibr">38</xref>]. In addition, only compound <bold>13</bold> showed effective inhibition against H<sub>1</sub>N<sub>1</sub> viral neuraminidase (NA), and docking of two isomers (<bold>13</bold> and <bold>14</bold>) into the active sites of NA showed that the <italic>E</italic> double bond was essential to achieve activity [<xref rid="bib38" ref-type="bibr">38</xref>]. Anthranoside C (<bold>15</bold>, <xref rid="fig5" ref-type="fig">Fig.&#x000a0;5</xref>) was purified from the marine sponge-derived <italic>Streptomyces</italic> sp. CMN-62 collected from Naozhou Island of the Guangdong Province, China [<xref rid="bib39" ref-type="bibr">39</xref>]. This compound exhibited inhibitory activity against H<sub>1</sub>N<sub>1</sub> with IC<sub>50</sub> value of 171&#x000a0;&#x003bc;M (ribavirin as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;133&#x000a0;&#x003bc;M) [<xref rid="bib39" ref-type="bibr">39</xref>].<fig id="fig5"><label>Fig.&#x000a0;5</label><caption><p>Chemical structures of compounds <bold>9</bold>&#x02013;<bold>15</bold> with anti-H<sub>1</sub>N<sub>1</sub> activities.</p></caption><alt-text id="alttext0035">Fig.&#x000a0;5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p><p id="p0050">Chemical investigation of the extract of sponge-associated fungus <italic>Truncatella angustata</italic> XSB-01-43 isolated from a finger sponge <italic>Amphimedon</italic> sp. collected from the reef at a depth of 10&#x000a0;m in Yongxing Island, Hainan Province of China, in June 2012, resulted in the isolation of truncateol O (<bold>16</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>
) [<xref rid="bib27" ref-type="bibr">27</xref>]. Compound <bold>16</bold> showed anti-H<sub>1</sub>N<sub>1</sub> activity with IC<sub>50</sub> value of 30.4&#x000a0;&#x003bc;M, which was stronger than that of oseltamivir (OSV), a positive control with IC<sub>50</sub> value of 46.7&#x000a0;&#x003bc;M [<xref rid="bib27" ref-type="bibr">27</xref>]. The marine sponge-derived <italic>Streptomyces</italic> sp. CMN-62 was associated with the marine green algae <italic>E.&#x000a0;prolifera</italic>, and produced three new phenolic polyketides, wailupemycin J (<bold>17</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>), <italic>R</italic>-wailupemycin K (<bold>18</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>), deoxyenterocin (<bold>19</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>) [<xref rid="bib28" ref-type="bibr">28</xref>]. It was first reported that compounds <bold>17</bold>, <bold>18</bold> and <bold>19</bold> displayed comparable anti-H<sub>1</sub>N<sub>1</sub> activity with 47.8%, 42.5% and 60.6% inhibitions, respectively at 50&#x000a0;&#x003bc;g/mL, while the positive control, ribavirin, with the inhibition rates of 45.3% at the same concentration [<xref rid="bib28" ref-type="bibr">28</xref>]. Two new meroterpenoids, chrodrimanins K (<bold>20</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>) and N (<bold>21</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>), as well as the known 3-hydroxypentacecilide A (<bold>22</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>) were separated from the fermentation broth of <italic>Penicillium</italic> sp. SCS-KFD09, which was gathered from a marine worm, <italic>Sipunculus nudus</italic>, from Haikou Bay, China [<xref rid="bib40" ref-type="bibr">40</xref>]. Compounds <bold>20</bold>, <bold>21</bold>, and <bold>22</bold> exhibited inhibitory activity against H<sub>1</sub>N<sub>1</sub> virus with IC<sub>50</sub> values of 74, 58, and 34&#x000a0;&#x003bc;M, respectively (ribavirin as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;103&#x000a0;&#x003bc;M) [<xref rid="bib40" ref-type="bibr">40</xref>]. The <italic>Aspergillus</italic> sp. SCSIO XWS02F40 derived from a marine sponge resulted in the discovery of two new asteltoxins named asteltoxins E (<bold>23</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6)</xref> and F (<bold>24</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>) [<xref rid="bib41" ref-type="bibr">41</xref>]. These compounds were shown to have significant anti-H<sub>3</sub>N<sub>2</sub> activities with IC<sub>50</sub> values of 6.2&#x000a0;&#x000b1;&#x000a0;0.08 and 8.9&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;&#x003bc;M, respectively. Additionally, compound <bold>23</bold> also showed inhibitory activity against H<sub>1</sub>N<sub>1</sub> with IC<sub>50</sub> value of 3.5&#x000a0;&#x000b1;&#x000a0;1.3&#x000a0;&#x003bc;M [<xref rid="bib41" ref-type="bibr">41</xref>]. Oseltamivir was used as the positive control with IC<sub>50</sub> values of 18.5 and 16.9&#x000a0;nM, respectively [<xref rid="bib41" ref-type="bibr">41</xref>]. A new compound named 6-<italic>O</italic>-demethylmonocerin (<bold>25</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>) and a known analogue, (+)-monocerin (<bold>26</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>), were obtained from marine <italic>Aspergillus</italic> sp. OUCMDZ-1583, and collected from the Xisha Islands of China [<xref rid="bib42" ref-type="bibr">42</xref>]. Compounds <bold>25</bold> and <bold>26</bold> showed anti-H<sub>1</sub>N<sub>1</sub> activity with IC<sub>50</sub> values of 172.4 and 175.5&#x000a0;&#x003bc;M, respectively (ribavirin as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;137.3&#x000a0;&#x003bc;M) [<xref rid="bib42" ref-type="bibr">42</xref>].<fig id="fig6"><label>Fig.&#x000a0;6</label><caption><p>Chemical structures of compounds <bold>16</bold>&#x02013;<bold>26</bold> with anti-H<sub>1</sub>N<sub>1</sub> activities.</p></caption><alt-text id="alttext0040">Fig.&#x000a0;6</alt-text><graphic xlink:href="gr6_lrg"/></fig></p><p id="p0055">Five new indole-diterpenoids (<bold>27</bold>&#x02013;<bold>31</bold>, <xref rid="fig7" ref-type="fig">Fig.&#x000a0;7</xref>
), were collected from the fermentation broth of <italic>Penicillium camemberti</italic> OUCMDZ-1492 that was isolated from an acidic marine niche, mangrove soil and mud, around the roots of <italic>Rhizophora apiculata</italic> at pH 5.0, together with emindole SB (<bold>32</bold>, <xref rid="fig7" ref-type="fig">Fig.&#x000a0;7</xref>), 21-isopentenylpaxilline (<bold>33</bold>, <xref rid="fig7" ref-type="fig">Fig.&#x000a0;7</xref>), and paspaline (<bold>34</bold>, <xref rid="fig7" ref-type="fig">Fig.&#x000a0;7</xref>), paxilline (<bold>35</bold>, <xref rid="fig7" ref-type="fig">Fig.&#x000a0;7</xref>) [<xref rid="bib43" ref-type="bibr">43</xref>]. When compared with ribavirin (IC<sub>50</sub>&#x000a0;=&#x000a0;113.1&#x000a0;&#x003bc;M), compounds <bold>27</bold>&#x02013;<bold>35</bold> displayed significant activities against influenza virus A (H<sub>1</sub>N<sub>1</sub>) virus with IC<sub>50</sub> values of 28.3, 38.9, 32.2, 73.3, 34.1, 26.2, 6.6, 77.9, and 17.7&#x000a0;&#x003bc;M, respectively [<xref rid="bib43" ref-type="bibr">43</xref>]. Moreover, the results showed that 3-oxo,4<italic>&#x003b2;</italic>-hydroxy, and 9-isopentenyl substitutions tended to increase the anti-H<sub>1</sub>N<sub>1</sub> activity of hexacyclic indole-diterpenoids [<xref rid="bib43" ref-type="bibr">43</xref>]. A marine-derived fungal strain, <italic>Aspergillus terreus</italic> SCSGAF0162, was isolated from the tissue of the gorgonian <italic>Echinogorgia aurantiaca</italic> collected from Sanya, Hainan Province, China [<xref rid="bib44" ref-type="bibr">44</xref>]. Asperterrestide A (<bold>36</bold>, <xref rid="fig7" ref-type="fig">Fig.&#x000a0;7</xref>), a new alkaloid purified from the fermentation broth of the <italic>A.&#x000a0;terreus</italic> SCSGAF0162, had a rare 3-OH-<italic>N</italic>-CH<sub>3</sub>-Phe residue and exhibited inhibitory activity against H<sub>1</sub>N<sub>1</sub> and H<sub>3</sub>N<sub>2</sub> virus with IC<sub>50</sub> values of 15 and 8.1&#x000a0;&#x003bc;M, respectively (ribavirin as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;20.2 and 0.41&#x000a0;&#x003bc;M, respectively) [<xref rid="bib44" ref-type="bibr">44</xref>].<fig id="fig7"><label>Fig.&#x000a0;7</label><caption><p>Chemical structures of compounds <bold>27</bold>&#x02013;<bold>36</bold> with anti-H<sub>1</sub>N<sub>1</sub> activities.</p></caption><alt-text id="alttext0045">Fig.&#x000a0;7</alt-text><graphic xlink:href="gr7_lrg"/></fig></p><p id="p0060">Cladosporisteroid B (<bold>37</bold>, <xref rid="fig8" ref-type="fig">Fig.&#x000a0;8</xref>
) was a new highly oxygenated sterol that was obtained from the extracts of the culture of a sponge-derived fungus <italic>Cladosporium</italic> sp. SCSIO41007 collected from the sea area near Xuwen County, Guangdong Province, China [<xref rid="bib45" ref-type="bibr">45</xref>]. Compound <bold>37</bold> showed weak anti-H<sub>3</sub>N<sub>2</sub> activity with IC<sub>50</sub> value of 16.2&#x000a0;&#x003bc;M (IC<sub>50</sub>&#x000a0;=&#x000a0;34.0&#x000a0;nM for the positive control oseltamivir) [<xref rid="bib45" ref-type="bibr">45</xref>]. The fungal strain <italic>Aspergillus ochraceus</italic> Jcma1F17 was isolated from a marine algae <italic>Coelarthrum</italic> sp. collected in Paracel Islands, South China Sea, which produced a new nitrobenzoyl sesquiterpenoid, 6<italic>&#x003b2;</italic>,9<italic>&#x003b1;</italic>-dihydroxy-14-<italic>p</italic>-nitrobenzoylcinnamolide (<bold>38</bold>, <xref rid="fig8" ref-type="fig">Fig.&#x000a0;8</xref>) [<xref rid="bib46" ref-type="bibr">46</xref>]. Nitrobenzoyl sesquiterpenoids are rare in natural sources, and <italic>Aspergillus</italic> species are the only sources of them. Compound <bold>38</bold> showed inhibitory activity against H<sub>3</sub>N<sub>2</sub> with IC<sub>50</sub> value of 17.0&#x000a0;&#x003bc;M (oseltamivir as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;0.008&#x000a0;&#x003bc;M) [<xref rid="bib46" ref-type="bibr">46</xref>].<fig id="fig8"><label>Fig.&#x000a0;8</label><caption><p>Chemical structures of compounds <bold>37</bold>&#x02013;<bold>38</bold> with anti-H<sub>3</sub>N<sub>2</sub> activities.</p></caption><alt-text id="alttext0050">Fig.&#x000a0;8</alt-text><graphic xlink:href="gr8_lrg"/></fig></p></sec><sec id="sec2.2"><label>2.2</label><title>Anti-HSV virus compounds</title><p id="p0065">HSV-1 is regularly correlative to oral-facial infections and encephalitis, whereas HSV-2 frequently causes genital ulcers worldwide [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib48" ref-type="bibr">48</xref>]. Herpes virus has a unique incubation period and physiological reactivation characteristics [<xref rid="bib49" ref-type="bibr">49</xref>]. The chronic incubation period makes the host susceptible to repeated attacks by virus activation and increases the possibility of virus transmission [<xref rid="bib50" ref-type="bibr">50</xref>]. At present, clinically effective anti-herpes virus drugs such as acyclovir, valacyclovir and other nucleoside analogues are mainly used as nucleoside inhibitors of DNA polymerase [<xref rid="bib51" ref-type="bibr">51</xref>]. However, due to antiherpetic drugs resistance and lack of validated vaccines for effective prevention, it is urgent to develop novel medicines against HSV virus [<xref rid="bib52" ref-type="bibr">52</xref>]. A strain of marine-derived <italic>Streptomyces koyangensis</italic> SCSIO 5802, which was isolated from the South China Sea at a depth of 3536&#x000a0;m, resulted in the discovery of a novel butenolide derivative, (4<italic>S</italic>)-10-hydroxy-10-methyl-11-oxo-dodec-2-en-1,4-olide (<bold>39</bold>, <xref rid="fig9" ref-type="fig">Fig.&#x000a0;9</xref>
) featuring octyl substitution at &#x003b3;-position [<xref rid="bib53" ref-type="bibr">53</xref>]. The new compound <bold>39</bold>, displayed anti-HSV-1 activity with EC<sub>50</sub> value of 25.4&#x000a0;&#x003bc;M (Ganciclovir as positive control, EC<sub>50</sub>&#x000a0;=&#x000a0;0.025&#x000a0;&#x003bc;M) [<xref rid="bib53" ref-type="bibr">53</xref>]. Xiao Liang et&#x000a0;al. separated simplicilliumtide J (<bold>40</bold>, <xref rid="fig9" ref-type="fig">Fig.&#x000a0;9</xref>), and verlamelins A and B (<bold>41</bold>, <bold>42</bold>, <xref rid="fig9" ref-type="fig">Fig.&#x000a0;9</xref>) from the deep-sea-derived fungal strain <italic>Simplicillium obclavatum</italic> EIODSF 020 [<xref rid="bib54" ref-type="bibr">54</xref>]. These compounds displayed significant anti-HSV-1 activity with IC<sub>50</sub> values of 14.0, 16.7, and 15.6&#x000a0;&#x003bc;M, respectively (acyclovir as positive control, EC<sub>50</sub>&#x000a0;=&#x000a0;3.0&#x000a0;&#x003bc;M). This is the first time to report the antiviral activity of these cyclic peptides [<xref rid="bib54" ref-type="bibr">54</xref>]. Two new anthraquinones, aspergilols H, I (<bold>43</bold>, <bold>44</bold>, <xref rid="fig9" ref-type="fig">Fig.&#x000a0;9</xref>) and coccoquinone A (<bold>45</bold>, <xref rid="fig9" ref-type="fig">Fig.&#x000a0;9</xref>) were purified from the deep-sea-associated fungus <italic>Aspergillus versicolor</italic> SCSIO 41502, collected from marine sediment sample at a depth of 2326&#x000a0;m from the South China Sea [<xref rid="bib55" ref-type="bibr">55</xref>]. These compounds displayed significant antiviral activity towards HSV-1 with EC<sub>50</sub> values of 4.68, 6.25, and 3.12&#x000a0;&#x003bc;M, respectively (acyclovir as positive control, EC<sub>50</sub>&#x000a0;=&#x000a0;3.0&#x000a0;&#x003bc;M) [<xref rid="bib55" ref-type="bibr">55</xref>].<fig id="fig9"><label>Fig.&#x000a0;9</label><caption><p>Chemical structures of compounds <bold>39</bold>&#x02013;<bold>45</bold> with anti-HSV activities.</p></caption><alt-text id="alttext0055">Fig.&#x000a0;9</alt-text><graphic xlink:href="gr9_lrg"/></fig></p><p id="p0070">Chemical investigation of the culture of <italic>Trichobotrys effuse</italic> DFFSCS021 that was isolated from the deep sea sediment collected from the South China Sea, resulted in the isolation of three new tetramic acid derivatives with a decalin ring, trichobotrysins A, B and D (<bold>46</bold>&#x02013;<bold>48</bold>, <xref rid="fig10" ref-type="fig">Fig.&#x000a0;10</xref>
) [<xref rid="bib56" ref-type="bibr">56</xref>]. Compounds <bold>46</bold>&#x02013;<bold>48</bold> possessed evidently anti-HSV-1 activity with IC<sub>50</sub> values of 3.08, 9.37, and 3.12&#x000a0;&#x003bc;M (acyclovir as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;3.5&#x000a0;&#x003bc;M). This is the first time to report the anti-HSV-1 activity of this type of compounds [<xref rid="bib56" ref-type="bibr">56</xref>]. Minghe Luo et&#x000a0;al. separated two novel hydroxamate-containing natural product cyclopeptides designated acremonpeptides A (<bold>49</bold>, <xref rid="fig10" ref-type="fig">Fig.&#x000a0;10)</xref> and B (<bold>50</bold>, <xref rid="fig10" ref-type="fig">Fig.&#x000a0;10</xref>), along with Al(III)&#x02212;acremonpeptide D (<bold>51</bold>, <xref rid="fig10" ref-type="fig">Fig.&#x000a0;10</xref>) from the extract of the fungal strain <italic>Acremonium persicinum</italic> SCSIO 115, which was isolated from a marine sediment sample collected in the South China Sea [<xref rid="bib57" ref-type="bibr">57</xref>]. These compounds <italic>in&#x000a0;vitro</italic> exhibited moderate antiviral activities for HSV-1 with EC<sub>50</sub> values of 16, 8.7, and 14&#x000a0;&#x003bc;M, respectively [<xref rid="bib57" ref-type="bibr">57</xref>]. A gorgonian sample collected from the South China Sea, Sanya, Hainan Province, resulted in the isolation of <italic>Aspergillus</italic> sp. SCSIO 41501, which further led to the isolation of two new linear peptides, namely, aspergillipeptides D and E (<bold>52</bold>, <bold>53</bold>, <xref rid="fig10" ref-type="fig">Fig.&#x000a0;10</xref>) [<xref rid="bib58" ref-type="bibr">58</xref>]. Compounds <bold>52</bold> and <bold>53</bold> exhibited evidently inhibition against herpes simplex virus type 1 (HSV-1) with IC<sub>50</sub> values of 9.5 and 19.8&#x000a0;&#x003bc;M under their non-cytotoxic concentrations against a Vero cell line, respectively [<xref rid="bib58" ref-type="bibr">58</xref>]. Additionally, compound <bold>53</bold> also had antiviral activity against acyclovir-resistant clinical isolates of HSV-1 [<xref rid="bib58" ref-type="bibr">58</xref>].<fig id="fig10"><label>Fig.&#x000a0;10</label><caption><p>Chemical structures of compounds <bold>46</bold>&#x02013;<bold>53</bold> with anti-HSV activities.</p></caption><alt-text id="alttext0060">Fig.&#x000a0;10</alt-text><graphic xlink:href="gr10_lrg"/></fig></p><p id="p0075">Xu-Hua Nong et&#x000a0;al. separated eight territrem derivatives along with nine butyrolactone derivatives from a marine-derived fungus <italic>Aspergillus terreus</italic> SCSGAF0162 under rice solid-state fermentation, which was gathered from South China Sea gorgonian coral <italic>Echinogorgia aurantiaca</italic> [<xref rid="bib59" ref-type="bibr">59</xref>]. All the isolated metabolites were evaluated for anti-HSV-1 activities, only 12&#x003b1;-dehydroxyisoterreulactone A (<bold>54</bold>, <xref rid="fig11" ref-type="fig">Fig.&#x000a0;11</xref>
), arisugacin A (<bold>55</bold>, <xref rid="fig11" ref-type="fig">Fig.&#x000a0;11</xref>), isobutyrolactone II (<bold>56</bold>, <xref rid="fig11" ref-type="fig">Fig.&#x000a0;11</xref>), and aspernolide A (<bold>57</bold>, <xref rid="fig11" ref-type="fig">Fig.&#x000a0;11</xref>) were shown to have obviously inhibitory effects with IC<sub>50</sub> values of 16.4&#x000a0;&#x000b1;&#x000a0;0.6, 6.34&#x000a0;&#x000b1;&#x000a0;0.4, 21.8&#x000a0;&#x000b1;&#x000a0;0.8 and 28.9&#x000a0;&#x000b1;&#x000a0;0.8&#x000a0;&#x003bc;g/mL, respectively [<xref rid="bib59" ref-type="bibr">59</xref>]. Balticolid (<bold>58</bold>, <xref rid="fig11" ref-type="fig">Fig.&#x000a0;11</xref>), a novel 12-membered macrolide, was separated from the extraction of the culture broth of the fungal strain 222 belonging to the Ascomycota, which was found in driftwood collected from the coast of the Greifswalder Bodden, Baltic Sea, Germany [<xref rid="bib60" ref-type="bibr">60</xref>]. This compound exhibited antiviral activity against HSV-1 with IC<sub>50</sub> value of 0.45&#x000a0;&#x003bc;M [<xref rid="bib60" ref-type="bibr">60</xref>].<fig id="fig11"><label>Fig.&#x000a0;11</label><caption><p>Chemical structures of compounds <bold>54</bold>&#x02013;<bold>58</bold> with anti-HSV activities.</p></caption><alt-text id="alttext0065">Fig.&#x000a0;11</alt-text><graphic xlink:href="gr11_lrg"/></fig></p><p id="p0080">Another study on the same fungal strain 222 resulted in the discovery of six novel naphthalenone derivatives, balticols A&#x02212;F (<bold>59</bold>&#x02013;<bold>64</bold>, <xref rid="fig12" ref-type="fig">Fig.&#x000a0;12</xref>
) [<xref rid="bib61" ref-type="bibr">61</xref>]. The balticols were tested at non-cytotoxic concentrations for their antiviral activity against Herpes simplex virus (HSV) type I. These compounds were found to showed inhibitory effect with IC<sub>50</sub> values of 1, 1, 1, 0.1, 0.01, 0.1&#x000a0;&#x003bc;g/mL, respectively [<xref rid="bib61" ref-type="bibr">61</xref>]. Balticol E had the most remarkable result with IC<sub>50</sub> value of 0.01&#x000a0;&#x003bc;g/mL against HSV-1 [<xref rid="bib61" ref-type="bibr">61</xref>].<fig id="fig12"><label>Fig.&#x000a0;12</label><caption><p>Chemical structures of compounds <bold>59</bold>&#x02013;<bold>64</bold> with anti-HSV virus activities.</p></caption><alt-text id="alttext0070">Fig.&#x000a0;12</alt-text><graphic xlink:href="gr12_lrg"/></fig></p></sec><sec id="sec2.3"><label>2.3</label><title>Others including HIV, HCV, RSV, EV71, DENV, CHIKV, and WEEV antivirals</title><p id="p0085">HIV-1 and HIV-2 can infect human beings and cause severe immunosuppression through decline of CD4<sup>+</sup> cells [<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib63" ref-type="bibr">63</xref>]. So far, over 30 antiretroviral drugs were on the market for the treatment of HIV infection and divided into six main groups: integrase inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors, and entry inhibitors [<xref rid="bib64" ref-type="bibr">64</xref>]. However, in the United States, the annual cost of the drugs per individual can be as high as $24,000 relying on the types of anti-HIV medicines [<xref rid="bib65" ref-type="bibr">65</xref>]. Two undescribed isoprenylated, truncateols O (<bold>2</bold>, <xref rid="fig6" ref-type="fig">Fig.&#x000a0;6</xref>) and P (<bold>65</bold>, <xref rid="fig13" ref-type="fig">Fig.&#x000a0;13</xref>
) were collected from the sponge-derived fungus <italic>Truncatella angustata</italic> [<xref rid="bib27" ref-type="bibr">27</xref>]. Compounds <bold>2</bold> and <bold>65</bold> showed anti-HIV effects by blocking HIV replication in one-cycle infection assay with IC<sub>50</sub> values of 39.0 and 16.1&#x000a0;&#x003bc;M, respectively [<xref rid="bib27" ref-type="bibr">27</xref>]. Moreover, though efavirenz (positive control) displaying stronger activity than the data raising from the isolated compounds, the lower cytotoxicity of the collected compounds (IC<sub>50</sub>&#x000a0;&#x0003e;&#x000a0;100&#x000a0;&#x003bc;M) in comparison with efavirenz (IC<sub>50</sub>&#x000a0;=&#x000a0;40.6&#x000a0;&#x003bc;M) suggested that these compounds were worthy for further observation as anti-HIV leads [<xref rid="bib27" ref-type="bibr">27</xref>]. Chemical investigation of the extract of marine-derived fungus <italic>Penicillium</italic> sp. IMB17-046 isolated from marine sediments collected from a mangrove swamp in Sanya, Hainan province, China, resulted in the isolation of trypilepyrazinol (<bold>66</bold>, <xref rid="fig3" ref-type="fig">Fig.&#x000a0;3</xref>, <xref rid="fig13" ref-type="fig">Fig.&#x000a0;13</xref>
<italic>&#x003b2;</italic>-hydroxyergosta-8,14,24 (28)-trien-7-one (<bold>67</bold>, <xref rid="fig13" ref-type="fig">Fig.&#x000a0;13</xref>) [<xref rid="bib66" ref-type="bibr">66</xref>]. These compounds exhibited broad-spectrum inhibitory activities against different types of viruses, including human immunodeficiency virus (HIV), and hepatitis C virus (HCV) [<xref rid="bib66" ref-type="bibr">66</xref>]. Compound <bold>66</bold> showed inhibitory activities against HIV-1 and HCV with IC<sub>50</sub> values of 4.6 and 7.7&#x000a0;&#x003bc;M, respectively. Compound <bold>67</bold> displayed anti-HIV-1 activity with IC<sub>50</sub> value of 3.5&#x000a0;&#x003bc;M [<xref rid="bib66" ref-type="bibr">66</xref>]. The marine derived <italic>Aspergillus niger</italic> SCSIO Jcsw6F30 was associated with a marine algae <italic>Sargassum</italic> sp. collected in Yongxing Island, South China Sea, in July 2012, and produced a novel 2-benzylpyridin-4-one containing metabolite, aspernigrin C (<bold>68</bold>, <xref rid="fig13" ref-type="fig">Fig.&#x000a0;13</xref>) and malformin C (<bold>69</bold>, <xref rid="fig13" ref-type="fig">Fig.&#x000a0;13</xref>) [<xref rid="bib67" ref-type="bibr">67</xref>]. These compounds exhibited obvious anti-HIV-1 activities with IC<sub>50</sub> values of 4.7&#x000a0;&#x000b1;&#x000a0;0.4, 1.4&#x000a0;&#x000b1;&#x000a0;0.06&#x000a0;&#x003bc;M, respectively (abacavir as a positive control, IC<sub>50</sub>&#x000a0;= 0.8 &#x000b1; 0.1 &#x003bc;M)[<xref rid="bib67" ref-type="bibr">67</xref>].<fig id="fig13"><label>Fig.&#x000a0;13</label><caption><p>Chemical structures of compounds <bold>65</bold>&#x02013;<bold>69</bold> with anti-HIV or anti-HCV activities.</p></caption><alt-text id="alttext0075">Fig.&#x000a0;13</alt-text><graphic xlink:href="gr13_lrg"/></fig></p><p id="p0090">RSV is considered to be the major pediatric respiratory pathogen, triggered by G protein combining host cell receptors [<xref rid="bib68" ref-type="bibr">68</xref>]. Only limited therapeutic compounds for RSV have been reported, such as paclizumab and ribavirin, accounting for the urgency to develop novel anti-RSV drugs [<xref rid="bib68" ref-type="bibr">68</xref>,<xref rid="bib69" ref-type="bibr">69</xref>]. Meilin Yu et&#x000a0;al. separated a new pregnane, 3<italic>&#x003b1;</italic>-hydroxy-7-ene-6,20-dione (<bold>70</bold>, <xref rid="fig14" ref-type="fig">Fig.&#x000a0;14</xref>
) from the extract of the fungal strain <italic>Cladosporium</italic> sp. WZ-2008-0042, which was isolated from the gorgonian <italic>Dichotella gemmacea</italic> collected at the Weizhou Island coral reef, in the South China Sea, in September 2008 [<xref rid="bib70" ref-type="bibr">70</xref>]. Compound <bold>70</bold> was tested for its inhibitory activity towards respiratory syncytial virus (RSV), displaying potential anti-RSV activity with IC<sub>50</sub> value of 0.12&#x000a0;mM (ribavirin as a positive control, IC<sub>50</sub>&#x000a0;= 0.08 mM) [<xref rid="bib70" ref-type="bibr">70</xref>]. A novel hexahydrobenzopyran derivative, named as cytosporin L (<bold>71</bold>, <xref rid="fig14" ref-type="fig">Fig.&#x000a0;14</xref>) and a known cytosporin D (<bold>72</bold>, <xref rid="fig14" ref-type="fig">Fig.&#x000a0;14</xref>) were obtained from the fungal strain <italic>Eutypella</italic> sp. isolated from the gorgonian <italic>Dichotella gemmacea</italic>, collected from the Weizhou coral reef in the South China Sea, Guangxi Province, China in 2008 [<xref rid="bib71" ref-type="bibr">71</xref>]. The isolated secondary metabolites were evaluated for their anti-virus activities [<xref rid="bib71" ref-type="bibr">71</xref>]. The antiviral activity against respiratory syncytial virus (RSV) induced cytopathogenicity in human laryngeal carcinoma (Hep-2) cell was determined by the cythopathic effect (CPE) inhibition assay, showing compounds <bold>71</bold> and <bold>72</bold> had significantly anti-RSV activities with IC<sub>50</sub> values of 72.01 and 30.25&#x000a0;&#x003bc;M, respectively [<xref rid="bib71" ref-type="bibr">71</xref>].<fig id="fig14"><label>Fig.&#x000a0;14</label><caption><p>Chemical structures of compounds <bold>70</bold>&#x02013;<bold>72</bold> with anti-RSV activities.</p></caption><alt-text id="alttext0080">Fig.&#x000a0;14</alt-text><graphic xlink:href="gr14_lrg"/></fig></p><p id="p0095">EV71 viruses can cause acute neurological disease in children, leading to heart and lung failure [<xref rid="bib72" ref-type="bibr">72</xref>]. Despite broad research with extensive target-based chemical design, developing drugs has failed to meet pharmacological expectations [<xref rid="bib73" ref-type="bibr">73</xref>]. Another study focused on a deep-sea-derived fungus <italic>Penicillium chrysogenum</italic> SCSIO 41001, which produced a citrinin dimer named penicitrinone F (<bold>73</bold>, <xref rid="fig15" ref-type="fig">Fig.&#x000a0;15</xref>
) [<xref rid="bib74" ref-type="bibr">74</xref>]. Using the CPE inhibition assay in accordance with protocols, this compound was evaluated for anti-EV71 activity, which exhibited moderate antivirus activity against EV71 with IC<sub>50</sub> value of 14.5&#x000a0;&#x003bc;M (ribavirin as positive control, IC<sub>50</sub>&#x000a0;=&#x000a0;13.3&#x000a0;&#x003bc;M) [<xref rid="bib74" ref-type="bibr">74</xref>]. Wei Fang et&#x000a0;al. isolated a novel nitrobenzoyl sesquiterpenoid 6<italic>&#x003b2;</italic>,9<italic>&#x003b1;</italic>-dihydroxy-14-<italic>p</italic>-nitrobenzoylcinnamolide (<bold>38</bold>, <xref rid="fig8" ref-type="fig">Fig.&#x000a0;8</xref>) collected from the extracts of the culture of marine-derived fungus <italic>Aspergillus ochraceus</italic> Jcma1F17 [<xref rid="bib46" ref-type="bibr">46</xref>]. This compound displayed anti-EV71 activity with IC<sub>50</sub> value of 9.4&#x000a0;&#x003bc;M [<xref rid="bib46" ref-type="bibr">46</xref>]. Ribavirin was used as the positive control against EV71 virus with IC<sub>50</sub> value of 0.6&#x000a0;&#x003bc;M [<xref rid="bib46" ref-type="bibr">46</xref>]. Chemical study of the extract of sponge-derived fungus <italic>Trichoderma</italic> sp. SCSIO41004 isolated from a <italic>Callyspongia</italic> sp. sponge collected from the sea area near Xuwen County, Guangdong Province, China, resulted in the isolation of ZSU-H85 A (<bold>74</bold>, <xref rid="fig15" ref-type="fig">Fig.&#x000a0;15</xref>) [<xref rid="bib75" ref-type="bibr">75</xref>]. Compound <bold>74</bold> was tested for antivirus activity against EV71 on Vero cells, showing anti-EV71 effect with IC<sub>50</sub> value of 25.7&#x000a0;&#x003bc;M (IC<sub>50</sub>&#x000a0;= 13.3 &#x003bc;M for the positive control ribavirin) [<xref rid="bib75" ref-type="bibr">75</xref>].<fig id="fig15"><label>Fig.&#x000a0;15</label><caption><p>Chemical structures of compounds <bold>73</bold>&#x02013;<bold>74</bold> with anti-EV71 activities.</p></caption><alt-text id="alttext0085">Fig.&#x000a0;15</alt-text><graphic xlink:href="gr15_lrg"/></fig></p><p id="p0100">DENV is considered as an urban disease, completing its cycle in humans by the biting of mosquito [<xref rid="bib76" ref-type="bibr">76</xref>]. Currently, it is vital to develop new antivirus drugs due to the absence of proper treatment or vaccination for DENF [<xref rid="bib76" ref-type="bibr">76</xref>]. A known fumiquinozaline, scequinadoline A (<bold>75</bold>, <xref rid="fig16" ref-type="fig">Fig.&#x000a0;16</xref>
), was obtained from the marine-derived fungus <italic>Dichotomomyces cejpii</italic> F31-1 isolated from the inner tissue of the soft coral <italic>Lobophytum crassum</italic> which was acquired from Hainan Sanya National Coral Reef Reserve, China [<xref rid="bib77" ref-type="bibr">77</xref>]. Compound <bold>75</bold> exerted obvious antivirus activity with 50% inhibition at 50&#x000a0;&#x003bc;M against dengue virus serotype 2 productions by standard plaque assay, equivalent to the positive control andrographlide at the same concentration, showing the potential for further development as a dengue virus inhibitor [<xref rid="bib77" ref-type="bibr">77</xref>].<fig id="fig16"><label>Fig.&#x000a0;16</label><caption><p>Chemical structure of compound <bold>75</bold> with anti-DENV activity.</p></caption><alt-text id="alttext0090">Fig.&#x000a0;16</alt-text><graphic xlink:href="gr16_lrg"/></fig></p><p id="p0105">Chikungunya Virus (CHIKV) is a mosquito-tansmitted Alphavirus that has been spreading rapidly, causing more than one million people infected. Although over-the-counter anti-inflammatory drugs can alleviate the symptoms, currently, there is no therapy to cure this disease [<xref rid="bib78" ref-type="bibr">78</xref>]. Debromoaplysiatoxin (<bold>76,</bold>
<xref rid="fig17" ref-type="fig">Fig.&#x000a0;17</xref>
) and anhydrodebromoaplysiatoxin (<bold>77,</bold>
<xref rid="fig17" ref-type="fig">Fig.&#x000a0;17)</xref>, and a new analogue, 3-methoxydebromoaplysiatoxin (<bold>78,</bold>
<xref rid="fig17" ref-type="fig">Fig.&#x000a0;17</xref>) were purified from the bioactive organic extracts of <italic>Trichodesmium erythraeum</italic> (TLT/PSK/001), collected from Pulau Seringat Kias, Singapore [<xref rid="bib79" ref-type="bibr">79</xref>]. Compounds <bold>76</bold>, <bold>77</bold> and 7<bold>8</bold> exhibited significant dose-dependent inhibition of CHIKV in post-treatment, with EC<sub>50</sub> values of 1.3, 22.3 and 2.7&#x000a0;&#x003bc;M, respectively [<xref rid="bib79" ref-type="bibr">79</xref>]. The antiviral mechanisms of these compounds probably targeted a step in the CHIKV replication cycle which occurred after viral entry. Compounds <bold>76</bold> and <bold>78</bold> may represent a new class of antiviral drugs, and further studies of essential pharmacophores probably produce modified leads with improved pharmacological properties [<xref rid="bib79" ref-type="bibr">79</xref>].<fig id="fig17"><label>Fig.&#x000a0;17</label><caption><p>Chemical structures of compounds <bold>76</bold>&#x02013;<bold>78</bold> with anti-CHIKV activities.</p></caption><alt-text id="alttext0095">Fig.&#x000a0;17</alt-text><graphic xlink:href="gr17_lrg"/></fig></p><p id="p0110">The Western Equine Encephalitis Virus (WEEV) belongs to the encephalitic alpha viruses, which can directly infect neurons leading to CNS inflammation and neuronal destruction. It can cause severe diseases in human with high fatality of 70%. Unfortunately, there are currently no licensed vaccines or antivirus drugs for alpha virus infections [<xref rid="bib80" ref-type="bibr">80</xref>]. Chemical investment of the extract of marine-derived <italic>Streptomyces kaviengensis</italic> (F7E2f) collected from the coast of New Ireland, Papua New Guinea, resulted in the isolation of antimycin A10a (<bold>79</bold>, <xref rid="fig18" ref-type="fig">Fig.&#x000a0;18</xref>
) [<xref rid="bib81" ref-type="bibr">81</xref>]. This compound exhibited potent activity against WEEV in cultured cells with IC<sub>50</sub> value of approximately 3&#x000a0;nM [<xref rid="bib81" ref-type="bibr">81</xref>]. The mechanism of action was that antimycin A1a can mediate in part by disruption of mitochondrial electron transport and pyrimidine biosynthesis [<xref rid="bib81" ref-type="bibr">81</xref>].<fig id="fig18"><label>Fig.&#x000a0;18</label><caption><p>Chemical structure of compound <bold>79</bold> with anti-WEEV activity.</p></caption><alt-text id="alttext0100">Fig.&#x000a0;18</alt-text><graphic xlink:href="gr18_lrg"/></fig></p></sec></sec><sec id="sec3"><label>3</label><title>Conclusions</title><p id="p0115">Many epidemics broke out over the centuries, which have killed millions of people. Nevertheless, few treatments are available for deadly virus infectious diseases till now. Additionally, a great large of antiviral drugs have been described with viral resistance, which remains an unsolved challenge for antivirus therapy [<xref rid="bib63" ref-type="bibr">63</xref>]. With increasing numbers of discovering novel types of viruses and drug resistant strains, it is urgent to develop new antiviral lead agents continuously. During the last decade, 79 marine microbes-derived natural products with 9 types of antivirus activities (anti-influenza, anti-HSV, anti-HIV, anti-HCV, anti-RSV, anti-EV71, anti-DNEV, anti-CHIKV, and anti-WEEV) were reported (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>), of which 40 compounds exhibited marked antiviral activities. Intriguingly, 18 compounds, rubrolide S (<bold>1</bold>), VLPs Q&#x02013;T (<bold>2</bold>&#x02013;<bold>5</bold>), (3Z,6S)-3-benzylidene-6-isobutylpiperazine-2,5-dione (<bold>10</bold>), albonoursin (<bold>11</bold>), truncateol O (<bold>16</bold>), <italic>R</italic>-wailupemycin K (<bold>18</bold>), chrodrimanins K and N (<bold>20</bold>&#x02013;<bold>21</bold>), 3-hydroxypentacecilide A (<bold>22</bold>), asteltoxins E and F (<bold>23</bold>&#x02013;<bold>24</bold>), asperterrestide A (<bold>36</bold>), trichobotrysins A (<bold>46</bold>) and D (<bold>48</bold>), and balticol E (<bold>63</bold>) displayed antivirus activities even stronger than the corresponding positive drugs. However, even if many <italic>in&#x000a0;vitro</italic> studies showed promising results on these compounds, a limited account of <italic>in&#x000a0;vivo</italic> studies has been performed to date. Statistically, these marine microbial compounds with antiviral activities were collected from different marine sources, including sediments, seawaters, algae, sponges, corals, worms as well as gorgonians (<xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref>). It is notable that over half of these compounds were isolated from marine sediments (50.6%). Marine <italic>Aspergillus</italic> (24.1%), <italic>Penicillium</italic> (21.5%) and <italic>Streptomyces</italic> (16.5%) were recognized as the dominant genera to produce these antiviral natural products (<xref rid="fig2" ref-type="fig">Fig.&#x000a0;2</xref>). Collectively, reasonable pharmacological screening of these compounds will offer promising leads for the development of antiviral medicines or antiviral adjuvants. However, so far only Ara-A derived from marine with anti-HSV activity has entered the market and few marine-derived compounds have reached the clinical trials. In the context of the global spread of COVID-19, it is necessary to continue research on novel antiviral natural products in the ocean, especially marine microbes. The marine environment is recognized as a unique but currently under-exploited resource in regard to identifying new compounds as potential therapeutic drugs. These compounds derived from the ocean may possess antiviral activity with unique mechanisms of action. Using chemosynthesis and biosynthesis strategies, it is possible to bring these antiviral natural products into further clinical development. Additionally, a multidisciplinary method that comprised of genomics, metabolomics, microbiology, natural products chemistry, and pharmacology may enrich the pipeline of novel antiviral drugs development with potential lead compounds, which will conduce to a worldwide search for clinically antivirus molecules.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0125">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Akram</surname><given-names>M.</given-names></name><name><surname>Tahir</surname><given-names>I.M.</given-names></name><name><surname>Shah</surname><given-names>S.M.A.</given-names></name><name><surname>Mahmood</surname><given-names>Z.</given-names></name><name><surname>Altaf</surname><given-names>A.</given-names></name><name><surname>Ahmad</surname><given-names>K.</given-names></name><name><surname>Munir</surname><given-names>N.</given-names></name><name><surname>Daniyal</surname><given-names>M.</given-names></name><name><surname>Nasir</surname><given-names>S.</given-names></name><name><surname>Mehboob</surname><given-names>H.</given-names></name></person-group><article-title>Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: a systematic review</article-title><source>Phytother Res.</source><volume>32</volume><year>2018</year><fpage>811</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">29356205</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>E.J.</given-names></name><name><surname>Doyle</surname><given-names>J.D.</given-names></name><name><surname>Uyeki</surname><given-names>T.M.</given-names></name></person-group><article-title>Influenza virus-related critical illness: prevention, diagnosis, treatment</article-title><source>Crit. Care</source><volume>23</volume><year>2019</year><fpage>214</fpage><pub-id pub-id-type="pmid">31189475</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name></person-group><article-title>Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development</article-title><source>Rev. Med. Virol.</source><volume>29</volume><year>2019</year><object-id pub-id-type="publisher-id">e2054</object-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Mu&#x000f1;oz</surname><given-names>J.</given-names></name><name><surname>Moreno</surname><given-names>S.</given-names></name></person-group><article-title>Strategies for the cure of HIV infection</article-title><source>Enferm. Infecc. Microbiol. Cl&#x000ed;n.</source><volume>37</volume><year>2019</year><fpage>265</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">29510860</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Priante</surname><given-names>E.</given-names></name><name><surname>Cavicchiolo</surname><given-names>M.E.</given-names></name><name><surname>Baraldi</surname><given-names>E.</given-names></name></person-group><article-title>RSV infection and respiratory sequelae</article-title><source>Minerva Pediatr.</source><volume>70</volume><year>2018</year><fpage>623</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">30379052</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Duan</surname><given-names>G.</given-names></name></person-group><article-title>Antiviral and inflammatory cellular signaling associated with enterovirus 71 infection</article-title><source>Viruses</source><volume>10</volume><year>2018</year><fpage>155</fpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Uno</surname><given-names>N.</given-names></name><name><surname>Ross</surname><given-names>T.M.</given-names></name></person-group><article-title>Dengue virus and the host innate immune response</article-title><source>Emerg. Microb. Infect.</source><volume>7</volume><year>2018</year><fpage>167</fpage></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Hoenen</surname><given-names>T.</given-names></name><name><surname>Groseth</surname><given-names>A.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name></person-group><article-title>Therapeutic strategies to target the Ebola virus life cycle</article-title><source>Nat. Rev. Microbiol.</source><volume>17</volume><year>2019</year><fpage>593</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">31341272</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X.</given-names></name></person-group><article-title>COVID-19: immunopathology and its implications for therapy</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>269</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">32273594</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Neiderud</surname><given-names>C.J.</given-names></name></person-group><article-title>How urbanization affects the epidemiology of emerging infectious diseases</article-title><source>Infect. Ecol. Epidemiol.</source><volume>5</volume><year>2015</year><fpage>27060</fpage><pub-id pub-id-type="pmid">26112265</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Strasfeld</surname><given-names>L.</given-names></name><name><surname>Chou</surname><given-names>S.</given-names></name></person-group><article-title>Antiviral drug resistance: mechanisms and clinical implications</article-title><source>Infect. Dis. Clin. North. Am.</source><volume>24</volume><year>2010</year><fpage>809</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">20674805</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Perez</surname><given-names>J.</given-names></name><name><surname>Schafer</surname><given-names>A.</given-names></name></person-group><article-title>Influenza virus: small molecule therapeutics and mechanisms of antiviral resistance</article-title><source>Curr. Med. Chem.</source><volume>25</volume><year>2018</year><fpage>5115</fpage><lpage>5127</lpage><pub-id pub-id-type="pmid">28933281</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Musharrafieh</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Validating enterovirus D68-2Apro as an antiviral drug target and the discovery of telaprevir as a potent D68-2Apro inhibitor</article-title><source>J.&#x000a0;Virol.</source><volume>93</volume><year>2019</year><object-id pub-id-type="publisher-id">e02221</object-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Novikova</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Freed</surname><given-names>E.O.</given-names></name><name><surname>Peng</surname><given-names>K.</given-names></name></person-group><article-title>Multiple roles of HIV-1 capsid during the virus replication cycle</article-title><source>Virol. Sin.</source><volume>34</volume><year>2019</year><fpage>119</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">31028522</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Cercq</surname><given-names>E.D.</given-names></name></person-group><article-title>ASPET otto krayer award lecture, molecular targets for antiviral agents</article-title><source>J.&#x000a0;Pharmacol. Exp. Therapeut.</source><volume>297</volume><year>2001</year><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>S.M.</given-names></name><name><surname>Pritchard</surname><given-names>S.M.</given-names></name><name><surname>Wudiri</surname><given-names>G.A.</given-names></name><name><surname>Trammell</surname><given-names>C.E.</given-names></name><name><surname>Nicola</surname><given-names>A.V.</given-names></name></person-group><article-title>Early steps in Herpes Simplex Virus infection blocked by a proteasome inhibitor</article-title><source>mBio</source><volume>10</volume><year>2019</year><object-id pub-id-type="publisher-id">e00732</object-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Yombi</surname><given-names>J.C.</given-names></name><name><surname>Mertes</surname><given-names>H.</given-names></name></person-group><article-title>Treatment as prevention for HIV infection: current data, challenges, and global perspectives</article-title><source>AIDS Rev.</source><volume>20</volume><year>2018</year><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">30264827</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Silveira</surname><given-names>L.T.C.</given-names></name><name><surname>Tura</surname><given-names>B.</given-names></name><name><surname>Santos</surname><given-names>M.</given-names></name></person-group><article-title>Systematic review of dengue vaccine efficacy</article-title><source>BMC Infect. Dis.</source><volume>19</volume><year>2019</year><fpage>750</fpage><pub-id pub-id-type="pmid">31455279</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Blunt</surname><given-names>J.W.</given-names></name><name><surname>Carroll</surname><given-names>A.R.</given-names></name><name><surname>Copp</surname><given-names>B.R.</given-names></name><name><surname>Davis</surname><given-names>R.A.</given-names></name><name><surname>Keyzers</surname><given-names>R.A.</given-names></name><name><surname>Prinsep</surname><given-names>M.R.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><volume>35</volume><year>2018</year><fpage>8</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">29335692</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Molinski</surname><given-names>T.F.</given-names></name><name><surname>Dalisay</surname><given-names>D.S.</given-names></name><name><surname>Lievens</surname><given-names>S.L.</given-names></name><name><surname>Saludes</surname><given-names>J.P.</given-names></name></person-group><article-title>Drug development from marine natural products</article-title><source>Nat. Rev. Drug Discov.</source><volume>8</volume><year>2009</year><fpage>69</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">19096380</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Gogineni</surname><given-names>V.</given-names></name><name><surname>Schinazi</surname><given-names>R.F.</given-names></name><name><surname>Hamann</surname><given-names>M.T.</given-names></name></person-group><article-title>Role of marine natural products in the genesis of antiviral agents</article-title><source>Chem. Rev.</source><volume>115</volume><year>2015</year><fpage>9655</fpage><lpage>9706</lpage><pub-id pub-id-type="pmid">26317854</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Nikapitiya</surname><given-names>C.</given-names></name></person-group><article-title>Exploring novel bioactive compounds from marine microbes</article-title><source>Adv. Food. Nutr. Res.</source><volume>65</volume><year>2012</year><fpage>363</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">22361200</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>G.</given-names></name><name><surname>Sunagawa</surname><given-names>S.</given-names></name></person-group><article-title>Marine microbial diversity</article-title><source>Curr. Biol.</source><volume>27</volume><year>2017</year><fpage>R489</fpage><lpage>R494</lpage><pub-id pub-id-type="pmid">28586685</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.M.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Bao</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>K.J.</given-names></name><name><surname>Jung</surname><given-names>J.H.</given-names></name></person-group><article-title>Marine-derived Aspergillus species as a source of bioactive secondary metabolites</article-title><source>Mar. Biotechnol.</source><volume>15</volume><year>2013</year><fpage>499</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">23709045</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Yasuhara-Bell</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>Marine compounds and their antiviral activities</article-title><source>Antivir. Res.</source><volume>86</volume><year>2010</year><fpage>231</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">20338196</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Barzkar</surname><given-names>N.</given-names></name><name><surname>Tamadoni</surname><given-names>J.S.</given-names></name><name><surname>Poorsaheli</surname><given-names>H.B.</given-names></name><name><surname>Vianello</surname><given-names>F.</given-names></name></person-group><article-title>Metabolites from marine microorganisms, micro, and macroalgae: immense scope for pharmacology</article-title><source>Mar. Drugs</source><volume>17</volume><year>2019</year><fpage>464</fpage></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Proksch</surname><given-names>P.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Lin</surname><given-names>W.</given-names></name></person-group><article-title>Truncateols O&#x02013;V, further isoprenylated cyclohexanols from the sponge-associated fungus Truncatella angustata with antiviral activities</article-title><source>Phytochemistry</source><volume>155</volume><year>2018</year><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">30077121</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>Phenolic polyketides from the marine alga-derived Streptomyces sp. OUCMDZ-3434</article-title><source>Tetrahedron</source><volume>73</volume><year>2017</year><fpage>5451</fpage><lpage>5455</lpage></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Chou</surname><given-names>K.</given-names></name></person-group><article-title>Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H<sub>1</sub>N<sub>1</sub> swine flu virus</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>386</volume><year>2009</year><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">19523442</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>E.C.</given-names></name></person-group><article-title>Influenza virus</article-title><source>Trends Microbiol.</source><volume>26</volume><year>2018</year><fpage>809</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">29909041</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Webster</surname><given-names>R.G.</given-names></name><name><surname>Webby</surname><given-names>R.J.</given-names></name></person-group><article-title>Influenza virus: dealing with a drifting and shifting pathogen</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>31</volume><year>2018</year><fpage>174</fpage><lpage>183</lpage></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Chou</surname><given-names>K.</given-names></name></person-group><article-title>Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H<sub>5</sub>N<sub>1</sub> virus</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>362</volume><year>2007</year><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">17707775</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Xin</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>New rubrolides from the marine-derived fungus Aspergillus terreus OUCMDZ-1925</article-title><source>J.&#x000a0;Antibiot.</source><volume>67</volume><year>2014</year><fpage>315</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">24326339</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Generation of methylated violapyrones with improved anti-influenza A virus activity by heterologous expression of a type III PKS gene in a marine Streptomyces strain</article-title><source>Bioorg. Med. Chem. Lett</source><volume>28</volume><year>2018</year><fpage>2865</fpage><lpage>2868</lpage><pub-id pub-id-type="pmid">30033162</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Gu</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Cladosins A&#x02013;E, hybrid polyketides from a deep-sea-derived fungus, Cladosporium sphaerospermum</article-title><source>J.&#x000a0;Nat. Prod.</source><volume>77</volume><year>2014</year><fpage>270</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">24499327</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Gu</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Sorbicatechols A and B, antiviral sorbicillinoids from the marine-derived fungus Penicillium chrysogenum PJX-17</article-title><source>J.&#x000a0;Nat. Prod.</source><volume>77</volume><year>2014</year><fpage>424</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">24495078</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Xi</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>Diketopiperazine derivatives from the marine-derived actinomycete Streptomyces sp. FXJ7.328</article-title><source>Mar. Drugs</source><volume>11</volume><year>2013</year><fpage>1035</fpage><lpage>1049</lpage><pub-id pub-id-type="pmid">23538868</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Gu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Aspulvinones from a mangrove rhizosphere soil-derived fungus <italic>Aspergillus terreus</italic> Gwq-48 with anti-influenza A viral (H<sub>1</sub>N<sub>1</sub>) activity</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>23</volume><year>2013</year><fpage>1776</fpage><lpage>1778</lpage><pub-id pub-id-type="pmid">23411074</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Che</surname><given-names>Q.</given-names></name><name><surname>Qiao</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Gu</surname><given-names>Q.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Anthranosides A&#x02013;C, anthranilate derivatives from a sponge-derived Streptomyces sp. CMN-62</article-title><source>Org. Lett.</source><volume>20</volume><year>2018</year><fpage>5466</fpage><lpage>5469</lpage><pub-id pub-id-type="pmid">30106304</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Chrodrimanins K&#x02013;N and related meroterpenoids from the fungus Penicillium sp. SCS-KFD09 isolated from a marine worm, Sipunculus nudus</article-title><source>J.&#x000a0;Nat. Prod.</source><volume>80</volume><year>2017</year><fpage>1039</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">28212032</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Qin</surname><given-names>X.</given-names></name><name><surname>Kaliyaperumal</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Asteltoxins with antiviral activities from the marine sponge-derived fungus Aspergillus sp</article-title><source>SCSIO XWS02F40, Molecules</source><volume>21</volume><year>2015</year><fpage>34</fpage></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>New &#x003b1;-glucosidase inhibitors from a marine sponge-derived fungus, Aspergillus sp. OUCMDZ-1583</article-title><source>RSC Adv.</source><volume>5</volume><year>2015</year><fpage>68852</fpage><lpage>68863</lpage></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Fu</surname><given-names>P.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>Indole-diterpenoids with anti-H<sub>1</sub>N<sub>1</sub> activity from the aciduric fungus Penicillium camemberti OUCMDZ-1492</article-title><source>J.&#x000a0;Nat. Prod.</source><volume>76</volume><year>2013</year><fpage>1328</fpage><lpage>1336</lpage><pub-id pub-id-type="pmid">23886345</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>He</surname><given-names>F.</given-names></name><name><surname>Bao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Tu</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>S.</given-names></name></person-group><article-title>Asperterrestide A, a cytotoxic cyclic tetrapeptide from the marine-derived fungus Aspergillus terreus SCSGAF0162</article-title><source>J.&#x000a0;Nat. Prod.</source><volume>76</volume><year>2013</year><fpage>1182</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">23806112</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>R.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Salendra</surname><given-names>L.</given-names></name><name><surname>Tu</surname><given-names>Z.</given-names></name></person-group><article-title>Three new highly oxygenated sterols and one new dihydroisocoumarin from the marine sponge-derived fungus Cladosporium sp. SCSIO41007</article-title><source>Steroids</source><volume>129</volume><year>2018</year><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">29223616</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>W.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Wan</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Ai</surname><given-names>W.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Tu</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Cytotoxic and antiviral nitrobenzoyl sesquiterpenoids from the marine-derived fungus Aspergillus ochraceus Jcma1F17</article-title><source>MedChemComm</source><volume>5</volume><year>2014</year><fpage>701</fpage><lpage>705</lpage></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Lodi</surname><given-names>G.</given-names></name><name><surname>Petti</surname><given-names>S.</given-names></name></person-group><article-title>The controversial natural history of oral herpes simplex virus type 1 infection.</article-title><source>Oral Dis.</source><volume>25</volume><year>2019</year><fpage>1850</fpage><lpage>1865</lpage><pub-id pub-id-type="pmid">31733122</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Groves</surname><given-names>M.J.</given-names></name></person-group><article-title>Genital herpes: a review</article-title><source>Am. Fam. Physician</source><volume>93</volume><year>2016</year><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">27281837</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Sauerbrei</surname><given-names>A.</given-names></name><name><surname>Schmitt</surname><given-names>S.</given-names></name><name><surname>Scheper</surname><given-names>T.</given-names></name><name><surname>Brandst&#x000e4;dt</surname><given-names>A.</given-names></name><name><surname>Wutzler</surname><given-names>P.</given-names></name></person-group><article-title>Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006</article-title><source>Euro Surveill.</source><volume>16</volume><year>2011</year><object-id pub-id-type="publisher-id">20005</object-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Birkmann</surname><given-names>A.</given-names></name><name><surname>Zimmermann</surname><given-names>H.</given-names></name></person-group><article-title>HSV antivirals - current and future treatment options</article-title><source>Curr. Opin. Virol.</source><volume>18</volume><year>2016</year><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">26897058</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Piret</surname><given-names>J.</given-names></name><name><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management</article-title><source>Antimicrob. Agents Chemother.</source><volume>55</volume><year>2011</year><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">21078929</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Schiffer</surname><given-names>J.T.</given-names></name><name><surname>Gottlieb</surname><given-names>S.L.</given-names></name></person-group><article-title>Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development</article-title><source>Vaccine</source><volume>37</volume><year>2017</year><fpage>7363</fpage><lpage>7371</lpage><pub-id pub-id-type="pmid">28958807</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Zang</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Ju</surname><given-names>J.</given-names></name></person-group><article-title>Octyl substituted butenolides from marine-derived Streptomyces koyangensi</article-title><source>Nat. Prod. Res.</source><year>2019</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/14786419.2019.1686368</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X.</given-names></name><name><surname>Nong</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Qi</surname><given-names>S.</given-names></name></person-group><article-title>Antifungal and antiviral cyclic peptides from the deep-sea-derived fungus Simplicillium obclavatum EIODSF 020</article-title><source>J.&#x000a0;Agric. Food Chem.</source><volume>65</volume><year>2017</year><fpage>5114</fpage><lpage>5121</lpage><pub-id pub-id-type="pmid">28578573</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Nong</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>S.</given-names></name></person-group><article-title>Anti-HSV-1, antioxidant and antifouling phenolic compounds from the deep-sea-derived fungus Aspergillus versicolor SCSIO 41502</article-title><source>Bioorg. Med. Chem. Lett</source><volume>27</volume><year>2017</year><fpage>787</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">28129981</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Nong</surname><given-names>X.H.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>S.</given-names></name></person-group><article-title>Cytotoxic antiviral tetramic acid derivatives from the deep-sea-derived fungus Trichobotrys effuse DFFSCS021</article-title><source>Tetrahedron</source><volume>47</volume><year>2016</year><fpage>9328</fpage><lpage>9332</lpage></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>M.</given-names></name><name><surname>Zang</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Ju</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name></person-group><article-title>Natural hydroxamate-containing siderophore acremonpeptides A&#x02013;D and an aluminum complex of acremonpeptide D from the marine-derived Acremonium persicinum SCSIO 115</article-title><source>J.&#x000a0;Nat. Prod.</source><volume>82</volume><year>2019</year><fpage>2594</fpage><lpage>2600</lpage><pub-id pub-id-type="pmid">31503476</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Nong</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Qi</surname><given-names>S.</given-names></name></person-group><article-title>Antiviral peptides from marine gorgonian-derived fungus Aspergillus sp. SCSIO 41501</article-title><source>Tetrahedron Lett.</source><volume>58</volume><year>2017</year><fpage>1151</fpage><lpage>1155</lpage></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Nong</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>S.</given-names></name></person-group><article-title>Territrem and butyrolactone derivatives from a marine-derived fungus Aspergillus terreus</article-title><source>Mar. Drugs</source><volume>12</volume><year>2014</year><fpage>6113</fpage><lpage>6124</lpage><pub-id pub-id-type="pmid">25522319</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Shushni</surname><given-names>M.A.M.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Mentel</surname><given-names>R.</given-names></name><name><surname>Lindequist</surname><given-names>U.</given-names></name></person-group><article-title>Balticolid: a new 12-membered macrolide with antiviral activity from an ascomycetous fungus of marine origin</article-title><source>Mar. Drugs</source><volume>9</volume><year>2011</year><fpage>844</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">21673893</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Shushni</surname><given-names>M.A.M.</given-names></name><name><surname>Mentel</surname><given-names>R.</given-names></name><name><surname>Lindequist</surname><given-names>U.</given-names></name><name><surname>Jansen</surname><given-names>R.</given-names></name></person-group><article-title>Balticols A&#x02013;F, new naphthalenone derivatives with antiviral activity, from an ascomycetous fungus</article-title><source>Chem. Biodivers.</source><volume>6</volume><year>2009</year><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">19235155</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Goodsell</surname><given-names>D.S.</given-names></name></person-group><article-title>Illustrations of the HIV life cycle</article-title><source>Curr. Top. Microbiol. Immunol.</source><volume>389</volume><year>2015</year><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">25716304</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Moghadamtousi</surname><given-names>S.Z.</given-names></name><name><surname>Nikzad</surname><given-names>S.</given-names></name><name><surname>Kadir</surname><given-names>H.A.</given-names></name><name><surname>Abubakar</surname><given-names>S.</given-names></name><name><surname>Zandi</surname><given-names>K.</given-names></name></person-group><article-title>Potential antiviral agents from marine fungi: an overview</article-title><source>Mar. Drugs</source><volume>13</volume><year>2015</year><fpage>4520</fpage><lpage>4538</lpage><pub-id pub-id-type="pmid">26204947</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>E.J.</given-names></name><name><surname>Nsanzimana</surname><given-names>S.</given-names></name></person-group><article-title>Have clinical trials in HIV finally matured</article-title><source>The Lancet HIV</source><volume>6</volume><year>2019</year><comment>e561&#x02212;e563</comment></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Kanters</surname><given-names>S.</given-names></name><name><surname>Mills</surname><given-names>E.J.</given-names></name><name><surname>Thorlund</surname><given-names>K.</given-names></name><name><surname>Bucher</surname><given-names>H.C.</given-names></name><name><surname>Ioannidis</surname><given-names>J.P.A.</given-names></name></person-group><article-title>Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and 400 systematic reviews and meta-analyses</article-title><source>Clin. Microbiol. Infect.</source><volume>20</volume><year>2014</year><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">24274661</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Jia</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>Z.</given-names></name><name><surname>Bi</surname><given-names>H.</given-names></name><name><surname>Xiao</surname><given-names>C.</given-names></name><name><surname>Cen</surname><given-names>S.</given-names></name><name><surname>Gan</surname><given-names>M.</given-names></name></person-group><article-title>Broad-spectrum antiviral natural products from the marine-derived Penicillium sp. IMB17-046</article-title><source>Molecules</source><volume>24</volume><year>2019</year><fpage>2821</fpage></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>W.</given-names></name><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Xun</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Aspernigrins with anti-HIV-1 activities from the marine-derived fungus Aspergillus Niger SCSIO Jcsw6F30</article-title><source>Bioorg. Med. Chem. Lett</source><volume>26</volume><year>2016</year><fpage>361</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">26711143</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Boyoglu-Barnum</surname><given-names>S.</given-names></name><name><surname>Chirkova</surname><given-names>T.</given-names></name><name><surname>Anderson</surname><given-names>L.J.</given-names></name></person-group><article-title>Biology of infection and disease pathogenesis to guide RSV vaccine development</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>1675</fpage><pub-id pub-id-type="pmid">31402910</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>S.A.</given-names></name><name><surname>Hendry</surname><given-names>R.M.</given-names></name><name><surname>Beeler</surname><given-names>J.A.</given-names></name></person-group><article-title>Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G</article-title><source>J.&#x000a0;Virol.</source><volume>73</volume><year>1999</year><fpage>6610</fpage><lpage>6617</lpage><pub-id pub-id-type="pmid">10400758</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Guan</surname><given-names>F.</given-names></name><name><surname>Cao</surname><given-names>F.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>A&#x000a0;new antiviral pregnane from a gorgonian-derived Cladosporium sp. Fungus</article-title><source>Nat. Prod. Res.</source><volume>32</volume><year>2018</year><fpage>1260</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">28641456</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name><name><surname>Zheng</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>A&#x000a0;new hexahydrobenzopyran derivative from the gorgonian-derived fungus Eutypella sp</article-title><source>Nat. Prod. Res.</source><volume>31</volume><year>2017</year><fpage>1640</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">28278631</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Mao</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Progress on the research and development of human enterovirus 71 (EV71) vaccines</article-title><source>Front. Med.</source><volume>7</volume><year>2013</year><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">23247645</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>K.X.</given-names></name><name><surname>Ng</surname><given-names>M.M.</given-names></name><name><surname>Chu</surname><given-names>J.J.H.</given-names></name></person-group><article-title>Developments towards antiviral therapies against enterovirus 71</article-title><source>Drug Discov. Today</source><volume>15</volume><year>2010</year><fpage>1041</fpage><lpage>1051</lpage><pub-id pub-id-type="pmid">20974282</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>B.</given-names></name><name><surname>Kaliaperumal</surname><given-names>K.</given-names></name><name><surname>Liao</surname><given-names>X.</given-names></name><name><surname>Tu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Structurally diverse secondary metabolites from a deep-sea-derived fungus Penicillium chrysogenum SCSIO 41001 and their biological evaluation</article-title><source>Fitoterapia</source><volume>117</volume><year>2017</year><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">28108327</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Tu</surname><given-names>Z.</given-names></name></person-group><article-title>Three new polyketides from the marine sponge-derived fungus Trichoderma sp. SCSIO41004</article-title><source>Nat. Prod. Res.</source><volume>32</volume><year>2018</year><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">28592143</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>M.G.</given-names></name><name><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>Dengue</article-title><source>Lancet</source><volume>385</volume><year>2015</year><fpage>453</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">25230594</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Smith</surname><given-names>D.R.</given-names></name><name><surname>Jaratsittisin</surname><given-names>J.</given-names></name><name><surname>Xiakeer</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name></person-group><article-title>Polyketides and alkaloids from the marine-derived fungus Dichotomomyces cejpii F31-1 and the antiviral activity of scequinadoline A against dengue virus</article-title><source>Mar. Drugs</source><volume>16</volume><year>2018</year><fpage>229</fpage></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Staveness</surname><given-names>D.</given-names></name><name><surname>Abdelnabi</surname><given-names>R.</given-names></name><name><surname>Near</surname><given-names>K.E.</given-names></name><name><surname>Nakagawa</surname><given-names>Y.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><name><surname>Delang</surname><given-names>L.</given-names></name><name><surname>Leyssen</surname><given-names>P.</given-names></name><name><surname>Wender</surname><given-names>P.A.</given-names></name></person-group><article-title>Inhibition of chikungunya virus-induced cell death by salicylate-derived bryostatin analogues provides additional evidence for a PKC-independent pathway</article-title><source>J.&#x000a0;Nat. Prod.</source><volume>79</volume><year>2016</year><fpage>680</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">26900711</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>D.K.</given-names></name><name><surname>Kaur</surname><given-names>P.</given-names></name><name><surname>Leong</surname><given-names>S.T.</given-names></name><name><surname>Tan</surname><given-names>L.T.</given-names></name><name><surname>Prinsep</surname><given-names>M.R.</given-names></name><name><surname>Chu</surname><given-names>J.J.</given-names></name></person-group><article-title>Anti-Chikungunya viral activities of aplysiatoxin-related compounds from the marine cyanobacterium Trichodesmium erythraeum</article-title><source>Mar. Drugs</source><volume>12</volume><year>2014</year><fpage>115</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">24394406</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Delekta</surname><given-names>P.C.</given-names></name><name><surname>Raveh</surname><given-names>A.</given-names></name><name><surname>Larsen</surname><given-names>M.J.</given-names></name><name><surname>Schultz</surname><given-names>P.J.</given-names></name><name><surname>Tamayo-Castillo</surname><given-names>G.</given-names></name><name><surname>Sherman</surname><given-names>D.H.</given-names></name><name><surname>Miller</surname><given-names>D.J.</given-names></name></person-group><article-title>The combined use of alphavirus replicons and pseudoinfectious particles for the discovery of antivirals derived from natural products</article-title><source>J.&#x000a0;Biomol. Screen</source><volume>20</volume><year>2015</year><fpage>673</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">25550354</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Raveh</surname><given-names>A.</given-names></name><name><surname>Delekta</surname><given-names>P.C.</given-names></name><name><surname>Dobry</surname><given-names>C.J.</given-names></name><name><surname>Peng</surname><given-names>W.</given-names></name><name><surname>Schultz</surname><given-names>P.J.</given-names></name><name><surname>Blakely</surname><given-names>P.K.</given-names></name><name><surname>Tai</surname><given-names>A.W.</given-names></name><name><surname>Matainaho</surname><given-names>T.</given-names></name><name><surname>Irani</surname><given-names>D.N.</given-names></name><name><surname>Sherman</surname><given-names>D.H.</given-names></name><name><surname>Miller</surname><given-names>D.J.</given-names></name></person-group><article-title>Discovery of potent broad spectrum antivirals derived from marine actinobacteria</article-title><source>PloS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e82318</object-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p>This research was funded by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (41706167), <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100013314</institution-id><institution>National 111 Project of China</institution></institution-wrap></funding-source> (D16013), and <funding-source id="gs3">Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Development Fund</funding-source>.</p></ack></back></article>